US20060167483A1 - Method, instruments, and kit for autologous transplantation - Google Patents
Method, instruments, and kit for autologous transplantation Download PDFInfo
- Publication number
- US20060167483A1 US20060167483A1 US11/375,183 US37518306A US2006167483A1 US 20060167483 A1 US20060167483 A1 US 20060167483A1 US 37518306 A US37518306 A US 37518306A US 2006167483 A1 US2006167483 A1 US 2006167483A1
- Authority
- US
- United States
- Prior art keywords
- support matrix
- cartilage
- implantable article
- collagen
- chondrocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2/2846—Support means for bone substitute or for bone graft implants, e.g. membranes or plates for covering bone defects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00491—Surgical glue applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/38—Joints for elbows or knees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2835—Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/30004—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
- A61F2002/30016—Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in hardness, e.g. Vickers, Shore, Brinell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30761—Support means for artificial cartilage, e.g. cartilage defect covering membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30762—Means for culturing cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0019—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in hardness, e.g. Vickers, Shore, Brinell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
Definitions
- the instant invention concerns the field of chondrocyte transplantation, bone and cartilage grafting, healing, joint repair and the prevention of arthritic pathologies.
- methods for the preparation of the graft site instruments for such preparation and for the autologous transplantation of cells to the prepared graft site.
- the articular chondrocytes are specialized mesenchymal derived cells found exclusively in cartilage.
- Cartilage is an avascular tissue whose physical properties depend on the extracellular matrix produced by the chondrocytes.
- endochondral ossification chondrocytes undergo a maturation leading to cellular hypertrophy, characterized by the onset of expression of type X collagen (Upholt, W. B. and Olsen, R. R., In: Cartilage Molecular Aspects (Hall, B & Newman, S, Eds.) CRC Boca Raton 1991, 43; Reichenberger, E. et al., Dev. Biol. 1991, 148, 562; Kirsch, T. et al., Differentiation, 1992, 52, 89; Stephens, M. et al., J. Cell Sci. 1993, 103, 1111).
- the teachings of the instant invention provide for effective, and efficient means of promoting the transplantation of cartilage and/or chondrocytes into a defect in an articulating joint or other cartilage covered bone surface, whereby cartilage is regenerated to fix the defect.
- the instant invention also provides for surgical instruments which are designed to prepare the graft site so as to facilitate the efficient integration of grafted material to the graft site.
- the instant invention provides a method for the effective treatment of articulating joint surface cartilage by the transplantation of chondrocytes in a suitable matrix, to a surface to be treated, with a hemostatic barrier and a cell-free covering-patch comprising; first placing a hemostatic barrier proximal to the surface to be treated, placing chondrocytes in a suitable matrix upon the surface to be treated distal to the hemostatic barrier, covering the surface to be treated with a cell-free covering-patch.
- a hemostatic barrier is a barrier which inhabits the penetration of vascularizing cells and tissue into the grafted material.
- the instant method provides for a hemostatic barrier that is a resorbable, semi-permeable material which inhibits or prohibits vascular infiltration through the barrier.
- the hemostatic barrier contains collagen.
- Cell-free is used herein as in the art, and means a material that is substantially free from intact cells which are capable of further cell division, promulgation or biological activity.
- a cell-free material is free from all intact nucleated cells.
- the instant method encompasses the use of a cell-free covering patch which contains a semi-permeable collagen matrix.
- the porous surface of the cell-free covering-patch is directed towards the implant material.
- the instant invention further provides for the autologous transplantation of collagen or chondrocytes to a graft site, wherein the graft site has first been prepared by surgical manipulation to better accept the grafted material.
- the graft site is sculpted such that the walls of the graft site are contoured in an undulating pattern such that the grafted material, when placed within the graft site and expanded to contact the graft site wall, provides resistance against removal or expulsion of the entire graft from the graft site.
- the instant invention further provides for surgical instruments designed to sculpt the graft site as taught by the method of the invention.
- the invention further provides for a kit for cartilage and/or chondrocyte transplantation onto the surface of an articular joint wherein said kit comprises a hemostatic barrier, cell-free semi-permeable covering-patch, and organic glue.
- the kit can optionally further provide one or more surgical instruments which can be used to sculpt the graft site in accordance with the methods of the instant invention.
- the present invention further provides an implant for cartilage repair in an animal.
- the implant is 1) a support matrix, 2) chondrocyte cells, and 3) a bio-compatible adhesive adhered to an edge of the support matrix.
- the support is absorbable by the animal.
- FIG. 1A is a drawing showing a typical articulating end of a bone.
- the bone material is covered on the articulating surface with a cartilaginous cap (shown by cross-hatching).
- FIG. 1B shows an example of where a defect or injury to the cartilaginous cap occurs (gap in the cross-hatching), and such a defect can be treated directly, enlarged slightly, or sculpted to accept the grafted material by surgical procedures prior to treatment.
- FIG. 1C shows how the hemostatic barrier (solid black, numbered 1 ) is placed within the defect in the cartilage cap to inhibit or prevent vascularization into regenerating cartilage, from the underlying bone.
- the chondrocytes to be implanted into the defect cavity are then layered on top of the hemostatic barrier.
- FIG. 2 is a drawing showing the treated defect (gap in cross-hatched area) in the cartilaginous cap (cross-hatched area) covered by a cell-free semi-permeable material (solid black, numbered 2 ) which is used to form a cap/patch or bandage over the defect site.
- This cap is fixed in place, either sutured to the edge of the cavity into healthy cartilage, or otherwise attached.
- This cap is covering the defective area of the joint into which the glue and cultured chondrocytes/cartilage transplant has been placed.
- FIG. 3A is a diagram illustrating the differential response to compression and shearing forces by harder and softer cartilage with subsequent zone of demarcation.
- FIG. 3B illustrates the graft site, after the defect has been sculpted to have undulating walls.
- FIG. 3C illustrates the sculpted graft site with the hemostatic barrier ( 1 ), transplanted material ( 3 ), and cell-free covering-patch ( 2 ) in place within the articular surface cartilage ( 4 ).
- FIG. 4A illustrates one embodiment of the surgical device of the instant invention showing cutting teeth ( 5 ) and protruding placement pin ( 6 ).
- FIG. 4B illustrates a second embodiment of the surgical device of the instant invention.
- FIG. 5 is a diagram illustrating the modified differential response to compression and shearing forces by harder cartilage and softer cartilage after sculpting the graft site.
- FIG. 6A is an MRI image of a pig knee showing cartilage defect in left (medial) condyle.
- FIG. 6B is an MRI image of the same pig knee three months after treatment.
- FIG. 7 illustrates a graft site or defect ( 23 ) without a hemostatic barrier, including a mixture of transplanted cells ( 21 ) and bio-compatible glue ( 22 ) on a support matrix ( 18 ) having a porous side, a cartilaginous material and transplanted material interface ( 30 ), cartilage ( 10 ), a bone material and cartilaginous material interface ( 12 ), a resorbable pin ( 24 ) and a bone material ( 14 ).
- This invention concerns the use of certain products that inhibit the formation of vascular tissue, for instance such as capillary loops projecting into the cartilage being established, during the process of autologous transplantation of chondrocytes into defects in the cartilage.
- vascular tissue for instance such as capillary loops projecting into the cartilage being established, during the process of autologous transplantation of chondrocytes into defects in the cartilage.
- the formation of vascular tissue from the underlying bone will tend to project into the new cartilage to be formed leading to appearance of cells other than the mesenchymal specialized chondrocytes desired.
- the contaminating cells introduced by the vascularization may give rise to encroachment and over-growth into the cartilage to be formed by the implanted chondrocytes.
- One of the types of commercial products which can be used in this invention is Surgicel® (Ethicon Ltd., UK) which is absorbable after a period of 7-14 days.
- Surgicel® Ethicon Ltd., UK
- the use of this material in the method of the instant invention is contrary to the normal use of a hemostatic device, such as Surgicel® as it is described in the package insert from Ethicon Ltd.
- a hemostatic material will act like a gel-like artificial coagulate. If red blood cells should be present within the full-thickness defect of articular cartilage that is capped by such a hemostatic barrier, these blood cells will be chemically changed to hematin, and thus rendered unable to induce vascular growth.
- a hemostatic product used as a re-vascularization inhibitory barrier with or without fibrin adhesives such as for example the Surgicel®, is effective for the envisioned method as taught by the instant invention.
- Another part of this invention is the use of a cell-free component, that is used as a patch covering the defective area of the joint into which the cultured chondrocytes/cartilage are being transplanted, using autologous chondrocytes for the transplantation.
- the method of the invention also contemplates the use of suitable allogenic chondrocytes or xenogenic chondrocytes for the repair of a cartilage defect.
- the instant invention teaches methods for effective repair or treatment of cartilage defects in articular joint bone surfaces which comprises administering an agent or device to block vascular invasion into the cartilage site to be repaired, and also providing for a cell-free barrier which will isolate the repair site and keep transplanted cells in place.
- the instant invention also provides for a kit comprising a hemostatic barrier component for insertion into the site to be repaired, such that there is effective inhibition of vascularization into the site to be repaired; and once the chondrocytes to be transplanted are placed into the site to be repaired, a cell-free semi-permeable barrier is capped over the repair site such that the transplanted chondrocytes are held in place, but are still able to gain access to nutrients.
- Certain aspects of the invention have been exemplified using an in vitro system to study the behavior of the chondrocytes when in contact with a certain product or a combination of certain products that inhibit the formation of vascular tissue.
- This in vitro testing predicts the ability of certain tested materials to inhibit vascularization, as will occur in vivo where capillary loops project into the cartilage being established during the process of autologous transplantation of chondrocytes into defects in the cartilage.
- Suitable hemostatic products will be characterized by having the ability to inhibit the growth, or invasion of vascular tissue, osteocytes, fibroblasts etc. into the developing cartilage.
- a suitable hemostatic material will achieve the goal of the method of the instant invention in that vascular and cellular invasion into developing cartilage should be prevented in order to optimize the formation of cartilage and achieve repair of the full-thickness of any defects in the articular cartilage.
- the hemostatic barrier will be stable for an extended period of time sufficient to allow for full cartilage repair, and then be able to be resorbed or otherwise broken down over time.
- Surgicel® W1912 an absorbable hemostat containing oxidized regenerated sterile cellulose; Lot GG3DH, Ethicon Ltd. UK.
- BioGide® a commercially available type I collagen matrix pad; Geistlich Sohne, Switzerland.
- Suitable organic glue material can be found commercially, such as for example Tisseel® or Tissucol® (fibrin based adhesive; Immuno AG, Austria), Adhesive Protein (Cat. #A-2707, Sigma Chemical, USA), and Dow Corning Medical Adhesive B (Cat. #895-3, Dow Corning, USA).
- the surgical instruments contemplated by the instant invention can be manufactured from metal and/or plastic suitable for making single-use disposable, or multi-use reusable surgical instruments.
- the cutting instrument may contain cutting teeth that are fully circular or flat, or anything in between.
- cartilage is a relatively soft material it may be advantageous to manufacture hardened plastic cutting edges which will be able to sculpt cartilage without being able to damage bone.
- Such cutting instruments can be manufactured to incorporate openings for administration of fluid, suction removal of cutting debris and fluid, and fiber optic threads for illumination and visualization of the defect site.
- the present invention includes cells 21 and glue 22 combined together as (1) a mixture of glue 22 and cells 21 or (2) one or more alternating layers of cells 21 and glue 22 on support matrix 18 .
- cells 21 are autologous chondrocyte cells to be transplanted into a defect 23 .
- Chondrocytes 21 are mixed, either homogeneously or non-homogeneously, with a suitable glue 22 before application of the chondrocyte/glue mixture to support matrix 18 .
- glue 22 and chondrocytes 21 are mixed immediately (that is, in the operating theater) before applying glue 22 and cells 21 to support matrix 18 , and implantation of the combination of glue 22 , cells 21 , and support matrix 18 into defect 23 .
- cells 21 and glue 22 are alternately applied in one or more layers to support matrix 18 .
- glue 22 is a bio-compatible glue, such as a fibrin glue, and more specifically either an autologous fibrin glue or a non-autologous fibrin glue.
- an autologous fibrin glue is used.
- chondrocytes 21 When chondrocytes 21 are combined with glue 22 on support matrix 23 , the glue/chondrocyte/support matrix combination is implanted into defect 23 either with or without a hemostatic barrier (as described herein) between bone 14 and the glue/chondrocyte/support matrix combination. In one embodiment, as shown in FIG. 2 , treated defect 23 does not contain a hemostatic barrier between bone 14 and the glue/chondrocyte/support matrix combination.
- the treatment of defect 23 according to the present invention similarly is accomplished without the use of a hemostatic barrier between the glue/chondrocyte/support matrix combination and the base of defect 23 .
- the combination of glue 22 and chrondrocytes 21 is present only on a portion of support matrix 18 .
- glue 22 and chondrocytes 21 preferably are only on an outer edge of a porous side of support matrix 18 .
- chondrocytes 21 and/or glue 22 penetrate into a porous side of support matrix 18 to a desired level, for example 2 to 50% of the depth of support matrix 18 .
- the porosity of support matrix 18 is greatest nearest a rough side, i.e., the side on which cells 21 and glue 22 are deposited, and least porous on the opposite side of support matrix 18 .
- the porosity of support matrix 18 is indicated by shading, where the darker shading indicates less porosity, and the lighter shading indicates greater porosity.
- chondrocytes 21 are applied to support matrix 18 , then covered with a layer of a suitable bio-compatible glue 22 .
- a layer of chondrocytes 21 on support matrix 18 and a single layer of glue 22 positioned over chondrocytes 21 is sufficient for effective treatment of a defect, more than one alternating layer of glue 22 and chondrocytes 21 can be used.
- a layer of bio-compatible glue 22 can be initially deposited on support matrix 18 , followed by a layer of chondrocytes 21 deposited on glue 22 .
- support matrix 18 is a sheet-like member capable of supporting growth of chondrocytes 21 and of providing physical integrity to the implantable article to facilitate manipulation thereof.
- support matrix 18 includes polypeptides or proteins such as collagen.
- support matrix 18 includes equine, porcine, bovine, ovine and chicken collagen.
- the collagen can be either Type I or Type II collagen.
- appropriate collagen support matrices 18 include ChondraGide® and BioGide® (commercially available type I collagen matrix pads; available from Geistlich Sohne, Switzerland). Additionally, support matrix 18 is reversibly deformable and has either a rough side that is porous, as described above, or a smooth side, or two rough sides.
- either side can be porous, in one embodiment as described herein, the rough side has greater porosity relative to the smooth side.
- Support matrix 18 and cells 21 positioned thereon can be optionally held in place in the defect by additional bio-compatible glue 22 and/or one or more biocompatible resorbable pins 24 , as shown in FIG. 7 .
- one or more portions of support matrix 18 is either solid or gel-like in character.
- Surgicel® was first treated with a fixative, such as glutaric aldehyde. Briefly, Surgicel® was treated with 0.6% glutaric aldehyde for 1 minute, followed by several washings to eliminate glutaric aldehyde residues that may otherwise be toxic to tissue. Alternatively, the Surgicel® was treated with the fibrin adhesive called Tisseel® prior to treatment with glutaric aldehyde as described in Example 2.
- a fixative such as glutaric aldehyde.
- the Surgicel® was also coated with an organic glue, in this example the glue used was Tisseel® but others can also be used. This product, together with the Surgicel® produces a useable barrier for the particular purpose of the invention. Any other hemostat or vascular inhibiting barrier could be used.
- the Tisseel® was mixed as described below.
- the Surgicel® was then coated with Tisseel® by spraying the Surgicel® material on both sides until soaked.
- the Tisseel® (fibrin glue) was then allowed to solidify at room temperature.
- the coated Surgicel® was then placed in 0.6% glutaric aldehyde for 1 minute and then washed with sterile physiological (0.9%) saline.
- the pH was then adjusted by PBS and/or with NaOH until pH was stable at 7.2 to 7.4. Afterwards the thus treated Surgicel® was then washed in tissue culture medium such as minimum essential medium/F12 with 15 mM Hepes buffer.
- Tisseel® as the fibrin adhesive to coat the Surgicel®.
- fibrin adhesive or glue may also be applied directly on the bottom of the lesion towards the bone, on which the Surgicel® is glued.
- the in vitro system used in lieu of in vivo testing, consisted of a NUNCLONTM Delta 6-well sterile disposable plate for cell research work (NUNC. InterMed, Roskilde, Denmark). Each well measures approximately 4 cm in diameter.
- the fibrin adhesive can be any adhesive which together with the fibrin component will produce a glue that can be tolerated in humans (Ihara, N, et al., Burns Incl. Therm. Inj., 1984, 10, 396).
- the invention also anticipates any other glue component that can be used in lieu of the fibrin adhesive.
- Tisseel® or Tissucol® Immuno AG, Vienna, Austria.
- the Tisseel® kit consists of the following components:
- the Tisseel® kit contains a DUPLOJECT® Application System.
- the fibrin adhesive or the two-component sealant using Tisseel® Kit is combined in the following manner according to the Immuno AG product insert sheet.
- Chondrocytes were grown in minimal essential culture medium containing HAM F12 and 15 mM Hepes buffer and 5 to 7.5% autologous serum in a CO 2 incubator at 37° C. and handled in a Class 100 laboratory at Verigen Europe A/S, Symbion Science Park, Copenhagen, Denmark. Other compositions of culture medium may be used for culturing the chondrocytes.
- the cells were trypsinized using trypsin EDTA for 5 to 10 minutes and counted using Trypan Blue viability staining in a Burker-Turk chamber. The cell count was adjusted to 7.5 ⁇ 10 5 cells per ml.
- One NUNCLONTM plate was uncovered in the Class 100 laboratory.
- the Surgicel® hemostatic barrier was cut to a suitable size fitting into the bottom of the well in the NUNCLONTM tissue culture tray. In this case a circle, of a size of approximately 4 cm (but could be of any possible size) and placed under aseptic conditions on the bottom in well in a NUNCLONTM Delta 6-well sterile disposable plate for cell research work (NUNC, InterMed, Roskilde, Denmark).
- the hemostatic barrier to be placed on the bottom of the well was pre-treated as described in Example 1. This treatment delays the absorption of the Surgicel significantly.
- This hemostatic barrier was then washed several times in distilled water and subsequently several times until non-reacted glutaraldehyde was washed out. A small amount of the cell culture medium containing serum was applied to be absorbed into the hemostatic barrier and at the same time keeping the hemostatic barrier wet at the bottom of the well.
- the medium was decanted, and cold refrigerated 2.5% glutaraldehyde containing 0.1M sodium salt of dimethylarsinic acid, (also called sodium cacodylate, pH is adjusted with HCl to 7.4), was added as a fixative for preparation of the cell and supporter (hemostatic barrier) for later preparation for electron microscopy.
- glutaraldehyde containing 0.1M sodium salt of dimethylarsinic acid also called sodium cacodylate, pH is adjusted with HCl to 7.4
- Chondrocytes were grown in minimal essential culture medium containing HAM F12 and 15 mM Hepes buffer and 5 to 7.5% autologous serum in a CO 2 incubator at 37 C. and handled in a Class 100 laboratory at Verigen Europe A/S, Symbion Science Park, Copenhagen, Denmark. Other compositions of culture medium may be used for culturing the chondrocytes.
- the cells were trypsinized using trypsin EDTA for 5 to 10 minutes and counted using Trypan Blue viability staining in a Burker-Turk chamber. The cell count was adjusted to 7.5 ⁇ 10 5 cells per ml.
- One NUNCLONTM plate was uncovered in the Class 100 laboratory.
- the Surgicel® (for use as the hemostatic barrier) was treated with 0.6% glutaric aldehyde for one minute as described in Example 1, and washed with 0.9% sterile sodium chloride solution or, preferably, with a buffer such as a PBS buffer or the culture medium such as MEM/F12, because the pH after the glutaric aldehyde treatment is 6.8 and should preferably be 7.0 to 7.5.
- the Tisseel® was applied on both sides of the Surgicel® using the DUPLOJECT® system, thus coating both sides of the Surgicel®, the patch intended to be used, with fibrin adhesive.
- the glue is left to dry under aseptic condition for at least 3 to 5 minutes.
- the “coated” hemostatic barrier was placed on the bottom of the well in a NUNCLOTM Delta 6-well sterile disposable plate for cell research work.
- a small amount of tissue culture medium containing serum was applied to be absorbed into the hemostatic barrier.
- tissue culture medium containing serum was placed directly on top of the Hemostat, dispersed over the surface of the hemostatic barrier.
- the plate was then incubated in a CO 2 incubator at 37° C. for 60 minutes.
- An amount of 2 to 5 ml of tissue culture medium containing 5 to 7.5% serum was carefully added to the well containing the cells avoiding splashing the cells by holding the pipette tip tangential to the side of the well when expelling the medium.
- the plate was incubated for 3 to 7 days with medium change at day 3. At the end of the incubation period the medium was decanted, and cold refrigerated, and 2.5% glutaraldehyde containing 0.1M sodium salt of dimethylarsinic acid, also called sodium cacodylate, pH is adjusted with HCl to 7.4, was added as a fixative for preparation of the cell and supporter (hemostatic barrier) for later preparation for electron microscopy.
- glutaraldehyde containing 0.1M sodium salt of dimethylarsinic acid also called sodium cacodylate
- Chondrocytes were grown in minimal essential culture medium containing HAM F12 and 15 mM Hepes buffer and 5 to 7.5% autologous serum in a CO 2 incubator at 37 C. and handled in a Class 100 laboratory at Verigen Europe A/S, Symbion Science Park, Copenhagen, Denmark.
- the cells were trypsinized using trypsin EDTA for 5 to 10 minutes and counted using Trypan Blue viability staining in a Burker-Turk chamber. The cell count was adjusted to 7.5 ⁇ 10 5 to 2 ⁇ 10 6 cells per ml.
- One NUNCLONTM plate was uncovered in the Class 100 laboratory.
- the Bio-Gide® can be used as a resorbable bilayer membrane which will be used as the patch or bandage covering the defective area of the joint into which the cultured chondrocytes are being transplanted as well as the hemostatic barrier.
- the Bio-Gide® is a pure collagen membrane obtained by standardized, controlled manufacturing processes (by E. D. Geistlich Sohne AG, CH-6110 Wolhusen). The collagen is extracted from veterinary certified pigs and is carefully purified to avoid antigenic reactions, and sterilized in double blisters by gamma irradiation.
- the bilayer membrane has a porous surface and a dense surface. The membrane is made of collagen type I and type III without further cross-linking or chemical treatment.
- the collagen is resorbed within 24 weeks.
- the membrane retains its structural integrity even when wet and it can be fixed by sutures or nails.
- the membrane may also be “glued” using fibrin adhesive such as Tisseel® to the neighboring cartilage or tissue either instead of sutures or together with sutures.
- the Bio-Gide® was un-covered in a class 100 laboratory and placed under aseptic conditions on the bottom of the wells in a NUNCLONTM Delta 6-well sterile disposable plate for cell research work,—either with the porous surface of the bilayer membrane facing up or with the dense surface facing up.
- tissue culture medium containing serum was placed directly on top of the Bio-Gide®, dispersed either over the porous or the dense surface of the Bio-Gide®.
- the plate was then incubated in a CO 2 incubator at 37° C. for 60 minutes. An amount of 2 to 5 ml of tissue culture medium containing 5 to 7.5% serum was carefully added to the well containing the cells avoiding splashing the cells by holding the pipette tip tangential to the side of the well when expelling the medium.
- the plate was incubated for 3 to 7 days with medium change at day 3. At the end of the incubation period the medium was decanted, and cold refrigerated 2.5% glutaraldehyde containing 0.1M sodium salt of dimethylarsinic acid, also called sodium cacodylate, pH is adjusted with HCl to 7.4, was added as fixative for preparation of the cell and the Bio-Gide® supporter with the cells either cultured on the porous surface or the dense surface. The Bio-Gide® patches were then sent for electron microscopy at Department of Pathology, Herlev Hospital, Denmark.
- Chondrocytes were grown in minimal essential culture medium containing HAM F12 and 15 mM Hepes buffer and 5 to 7.5% autologous serum in a CO 2 incubator at 37° C. and handled in a Class 100 laboratory at Verigen Europe A/S, Symbion Science Park, Copenhagen, Denmark.
- the cells were trypsinized using trypsin EDTA for 5 to 10 minutes and counted using Trypan Blue viability staining in a Burker-Turk chamber. The cell count was adjusted to 7.5 ⁇ 10 6 to 2 ⁇ 10 6 cells per ml.
- One NUNCLONTM plate was uncovered in the Class 100 laboratory.
- the Bio-Gide® used as a resorbable bilayer membrane may also be used together with an organic glue such as Tisseel® with additional, significantly higher content of Aprotinin than normally found in Tisseel®, as described in the product insert.
- an organic glue such as Tisseel® with additional, significantly higher content of Aprotinin than normally found in Tisseel®, as described in the product insert.
- the Tisseel® is applied to the bottom of the well of the NUNCLONTM plate, and allowed to solidify incompletely.
- a collagen patch such as a Bio-Gide® is then applied over the Tisseel® and glued to the bottom of the well.
- This combination of Bio-Gide® and Tisseel® is designed to be a hemostatic barrier that will inhibit or prevent development or infiltration of blood vessels into the chondrocyte transplantation area.
- This hybrid collagen patch can now be used for both a hemostatic barrier at the bottom of the lesion (most proximal to the surface to be repaired) as well as a support for cartilage formation because the distal surface can be the porous side of the collagen patch and thus encourage infiltration of chondrocytes and cartilage matrix.
- this hybrid collagen patch can also be used to cover the top of the implant with the collagen porous surface directed down towards the implanted chondrocytes and the barrier forming the top.
- the hybrid collagen patch, with elevated Aprotinin component may also be used without any organic glue such as Tisseel® and placed within the defect directly, adhering by natural forces.
- the collagen patch can be used both as the hemostatic barrier, and the cell-free covering of the repair/transplant site, with the porous surfaces of the patches oriented towards the transplanted chondrocytes/cartilage.
- Another variant would use a collagen patch which consists of type II collagen (i.e. from Geistlich Sohne AG, CH-6110 Wolhusen).
- the instant invention provides for a hybrid collagen patch where said patch is a collagen matrix with elevated levels of aprotinin component, preferably about 25,000 KIU/ml, in association with an organic matrix glue, where the collagen component is similar to the Bio-Gide® resorbable bilayer material or Type II collagen, and the organic glue is similar to the Tisseel® material.
- the hybrid collagen patch does not use any organic glue to adhere to the site of the repair.
- a marginal zone zone of demarcation
- This marginal zone will be most pronounced if the graft site is prepared for the graft by creating straight, smooth walls cut in a linear fashion. The shearing and compression forces across such a marginal zone (as illustrated in FIG. 3A ) will exert great force to dislodge the graft when the graft site is cut in a linear fashion.
- This marginal zone, and differential movement of materials along this zone will inhibit confluent healing between the grafted material and the surrounding material.
- the graft material is softer than the surrounding material, however, in some instances of osteoarthritis disease, the surrounding cartilage may in fact be softer than the implanted chondrocytes/cartilage.
- the method of the invention teaches the use of surgical instruments to sculpt the walls of the graft site such that the walls are non-linear, and thus provide for undulated surfaces. It is also possible to shape the graft site such that the diameter of the site proximal to the bone surface is of a greater dimension then the opening distal to the bone, and at the surface of the cartilage.
- the preferred embodiment describes the sculpting of the walls of the graft site in an fashion similar to a threaded opening for receiving a bolt or screw (as illustrated in FIG. 3B ), thus providing mechanical resistance to the compression and or ejection of the grafted material from the graft site which can be described as “male” and “female” threading.
- the surgical instruments contemplated by the instant invention can be manufactured from metal and/or plastic suitable for making single-use disposable, or multi-use reusable surgical instruments.
- cartilage is a relatively soft material it may be advantageous to manufacture hardened plastic cutting edges which will be able to sculpt cartilage without being able to damage bone.
- Such cutting instruments can be manufactured to incorporate openings for administration of fluid, suction removal of cutting debris and fluid, and fiber optic threads for illumination and visualization of the defect site.
- the base of the instrument may have protruding point or pin-like structure which will assist in guiding and placing the instrument in the graft site. Of course such a pin would be designed to minimized damage to the underlying bone.
- the cutting surface of the instrument may be single toothed, or multi-toothed, or describe a screw-like pattern such as that in a metal tap used to generate threaded holes in metal parts
- the characteristic required of the cutting instrument is that the resulting sculpted sides of the graft site is undulated, and non-linear.
- the cutting edge of the instrument can be shaped similar to that shown in FIG. 4A , or as in FIG. 4B .
- the cutting edge maybe flat, or circular in that it wraps around the diameter of the cutting instrument. Many other shapes can be designed to accomplish the purpose of the method of the invention to create an interface which provides for mechanical resistance to differential reaction to compression and shearing forces on the transplanted material and the surrounding material.
- a four month old mixed Yorkshire breed pig was subjected to general anesthesia and placed on its back. The pig was washed and draped in a surgical suite at Harrington Arthritis Research Center, Phoenix, Ariz. The entire surgical procedure was performed aseptically. The left hind-leg and adjacent abdomen and inguinal area was cleaned with iodine. The knee joint was localized, and the patella localized. A medial incision was performed approximately 3 cm from the posterior part of the patella and the several subcutis, muscle layers and ligaments was cut approximately in order to get access to the medial femoral condyle.
- a lesion was prepared in the white cartilage on the medial part of the medial condyle, leaving a 0.5 to 1 cm margin to the edge of the cartilage covering the posterior-medial part of the condyle (left condyle, FIG. 6A ).
- the 0.5 to 1 cm defect was placed in a caudal weight bearing part of the medial condyle.
- the entire surgical procedure was done without tourniquet on the left femur. The different layers and skin was sutured appropriately.
- Adhesive Protein A-2707, Sigma Chemical, USA
- Adhesive Protein A-2707, Sigma Chemical, USA
- a second BioGide® was cut somewhat bigger in circumference than the lesion and was placed with dense side up (thus the porous side down towards the graft) as described above.
- This non-cellular covering-pad was then sutured over the cavity, leaving one edge open, where the chondrocyte to be explanted could be injected.
- the surrounding part of the edge of the pad was covered with the second glue, Dow Corning Medical Adhesive B (Cat. #895-3, Dow Corning, USA).
- This second glue dried much faster and more efficiently than the first glue. It was found that during this particular procedure, the first glue had not dried sufficiently to hold the hemostatic barrier in place when suturing of the cap was attempted. Thus, the main barrier formed on the proximal surface of the graft site was by the glue itself.
- the chondrocyte cell suspension (about 0.6 ml) was drawn up into the barrel of the syringe.
- a 23 gauge short needle was switched for the 16 gauge needle, and the cell suspension was injected under the sutured covering-patch into the graft site (about 10 ⁇ 10 6 cells).
- the open edge of the cap was then glued prior to removal of the needle, and the needle carefully withdrawn. No leakage of cells was seen.
- the wound was sutured and as above, no tourniquet was used, no bleeding was observed.
- the final skin layers were sutured. No protrusion of the skin occurred after suturing, which indicates that there was no hematoma. Postoperative recovery was uneventful.
- FIG. 6A is an MRI image of a pig knee showing the cartilage defect created in the knee (left condyle, the medial condyle), and FIG. 6B is an MRI image of the same pig knee three months after treatment showing repair of the defect.
- kits comprising the components useful for practicing the method of the invention, will allow for the convenient practice of the method of the invention in a surgical setting.
- a kit of the invention will provide sterile components suitable for easy use in the surgical environment, and will provide a suitable hemostatic barrier, suitable covering patch, and if needed organic glue.
- a kit of the invention may also provide sterile, cell-free matrix material suitable for supporting autologous chondrocytes that are to be implanted into an articular joint surface defect.
- a kit of the invention contains a Surgicel® hemostatic barrier and a Bio-Gide® covering patch with suitable coating of Tisseel® organic glue, where the Surgicel® and Bio-Gide® have been treated according to the teachings of the invention to increase the time till resorption.
- Tisseel® is pre-coated
- the Tisseel® is supplemented with additional aprotinin to increase time till resorption.
- the hemostatic barrier and covering-patch are both a semi-permeable collagen matrix which is treated to extend the time till resorption of the material. It is also possible to provide Tisseel® glue in enhanced form as a separate component to be applied as needed because of the inherent variability and unique circumstances every repair/transplantation procedure will encounter.
- a further embodiment of the kit will include a surgical instrument as described in Example 7 above.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
An implantable article for cartilage repair by implantation in an animal. The implantable article includes a support matrix, and chondrocyte cells and a bio-compatible adhesive adhered to an edge of the support matrix, wherein the support matrix is absorbable by the animal. The support matrix is a biocompatible material such as collagen, and the adhesive is autologous fibrin.
Description
- This application is a continuation-in-part of U.S. patent application Ser. No. 09/690,252, filed Oct. 17, 2000, which is a continuation of application Ser. No. 09/320,246, filed May 26, 1999 (now U.S. Pat. No. 6,283,980), which in turn is a continuation of U.S. patent application Ser. No. 08/857,090, filed May 15, 1997 (now U.S. Pat. No. 5,989,269), which is a continuation-in-part of U.S. patent application Ser. No. 08/704,891, filed Aug. 30, 1996 (now U.S. Pat. No. 5,759,190), all of which are hereby incorporated by reference in their entirety.
- The instant invention concerns the field of chondrocyte transplantation, bone and cartilage grafting, healing, joint repair and the prevention of arthritic pathologies. In particular methods for the preparation of the graft site, instruments for such preparation and for the autologous transplantation of cells to the prepared graft site.
- More than 500,000 arthroplastic procedures and total joint replacements are performed each year in the United States. Approximately the same number of similar procedures are performed in Europe. Included in these numbers are about 90,000 total-knee replacements and around 50,000 procedures to repair defects in the knee per year in Europe. The number of procedures are essentially the same in the U.S. (In: Praemer A., Furner S., Rice, D. P., Musculoskeletal conditions in the United States, American Academy of Orthopaedic Surgeons, Park Ridge, Ill., 1992, 125). A method for regeneration-treatment of cartilage would be most useful, and could be performed at an earlier stage of joint damage, thus reducing the number of patients needing artificial joint replacement surgery. With such preventative methods of treatment, the number of patients developing osteoarthritis would also decrease.
- Techniques used for resurfacing the cartilage structure in joints have mainly attempted to induce the repair of cartilage using subchondral drilling, abrasion and other methods whereby there is excision of diseased cartilage and subchondral bone, leaving vascularized cancellous bone exposed (Insall, J., Clin. Orthop. 1974, 101, 61; Ficat R. P. et al, Clin Orthop. 1979, 144, 74; Johnson L. L., In: Operative Arthroscopy, McGinty J. B., Ed., Raven Press, New York, 1991, 341).
- Coon and Cahn (Science 1966, 153, 1116) described a technique for the cultivation of cartilage synthesizing cells from chick embryo somites. Later Cahn and Lasher (PNAS USA 1967, 58, 1131) used the system for analysis of the involvement of DNA synthesis as a prerequisite for cartilage differentiation. Chondrocytes respond to both EFG and FGF by growth (Gospodarowicz and Mescher, J. Cell Physiology 1977, 93, 117), but ultimately lose their differentiated function (Benya et al., Cell 1978, 15, 1313). Methods for growing chondrocytes were described and are principally being used with minor adjustments by Brittberg, M. et al. (New Engl. J. Med. 1994, 331, 889). Cells grown using these methods were used as autologous transplants into knee joints of patients. Additionally, Kolettas et al. (J. Cell Science 1995, 108, 1991) examined the expression of cartilage-specific molecules such as collagens and proteoglycans under prolonged cell culturing. They found that despite morphological changes during culturing in monolayer cultures (Aulthouse, A. et al., In Vitro Cell Dev. Biol., 1989, 25, 659; Archer, C. et al., J. Cell Sci. 1990, 97, 361; Hanselmann, H. et al., J. Cell Sci. 1994, 107, 17; Bonaventure, J. et al., Exp. Cell Res. 1994, 212, 97), when compared to suspension cultures grown over agarose gels, alginate beads or as spinner cultures (retaining a round cell morphology) tested by various scientists did not change the chondrocyte—expressed markers such as types II and IX collagens and the large aggregating proteoglycans, aggrecan, versican and link protein did not change (Kolettas, E. et al., J. Cell Science 1995, 108, 1991).
- The articular chondrocytes are specialized mesenchymal derived cells found exclusively in cartilage. Cartilage is an avascular tissue whose physical properties depend on the extracellular matrix produced by the chondrocytes. During endochondral ossification chondrocytes undergo a maturation leading to cellular hypertrophy, characterized by the onset of expression of type X collagen (Upholt, W. B. and Olsen, R. R., In: Cartilage Molecular Aspects (Hall, B & Newman, S, Eds.) CRC Boca Raton 1991, 43; Reichenberger, E. et al., Dev. Biol. 1991, 148, 562; Kirsch, T. et al., Differentiation, 1992, 52, 89; Stephens, M. et al., J. Cell Sci. 1993, 103, 1111).
- Excessive degradation of type II collagen in the outer layers or articular surfaces of joints is also caused by osteoartritis. The collagen network is accordingly weakened and subsequently develops fibrillation whereby matrix substances such as proteoglycans are lost and eventually displaced entirely. Such fibrillation of weakened osteoarthritic cartilage can reach down to the calcified cartilage and into the subchondral bone (Kempson, G. E. et al., Biochim. Biophys. Acta 1976, 428, 741; Roth, V. and Mow, V. C., J. Bone Joint Surgery, 1980, 62A, 1102; Woo, S. L.-Y. et al., in Handbook of Bioengineering (R. Skalak and S. Chien eds.), McGraw-Hill, New York, 1987, pp. 4.1-4.44).
- Descriptions of the basic development, histological and microscopic anatomy of bone, cartilage and other such connective tissues can be found for example in Wheater, Burkitt and Daniels, Functional Histology, 2nd Edition, (Churchill Livingstone, London, 1987, Chp. 4). Descriptions of the basic histological anatomy of defects in bone, cartilage and other connective tissue can be found for example in Wheater, Burkitt, Stevens and Lowe, Basic Histopathology (Churchill Livingstone, London, 1985, Chp. 21).
- Despite the advances in cultivating chondrocytes, and manipulating bone and cartilage, there has not been great success with the attempts to transplant cartilage or chondrocytes for the repair of damaged articulating surfaces. The teachings of the instant invention provide for effective, and efficient means of promoting the transplantation of cartilage and/or chondrocytes into a defect in an articulating joint or other cartilage covered bone surface, whereby cartilage is regenerated to fix the defect. The instant invention also provides for surgical instruments which are designed to prepare the graft site so as to facilitate the efficient integration of grafted material to the graft site.
- The instant invention provides a method for the effective treatment of articulating joint surface cartilage by the transplantation of chondrocytes in a suitable matrix, to a surface to be treated, with a hemostatic barrier and a cell-free covering-patch comprising; first placing a hemostatic barrier proximal to the surface to be treated, placing chondrocytes in a suitable matrix upon the surface to be treated distal to the hemostatic barrier, covering the surface to be treated with a cell-free covering-patch. A hemostatic barrier, as will be further described below, is a barrier which inhabits the penetration of vascularizing cells and tissue into the grafted material. In particular, the instant method provides for a hemostatic barrier that is a resorbable, semi-permeable material which inhibits or prohibits vascular infiltration through the barrier. In one embodiment the hemostatic barrier contains collagen. Cell-free, is used herein as in the art, and means a material that is substantially free from intact cells which are capable of further cell division, promulgation or biological activity. In a preferred embodiment, a cell-free material is free from all intact nucleated cells. In one embodiment, the instant method encompasses the use of a cell-free covering patch which contains a semi-permeable collagen matrix. In one preferred embodiment of the method, the porous surface of the cell-free covering-patch is directed towards the implant material.
- The instant invention further provides for the autologous transplantation of collagen or chondrocytes to a graft site, wherein the graft site has first been prepared by surgical manipulation to better accept the grafted material. In one embodiment, the graft site is sculpted such that the walls of the graft site are contoured in an undulating pattern such that the grafted material, when placed within the graft site and expanded to contact the graft site wall, provides resistance against removal or expulsion of the entire graft from the graft site. The instant invention further provides for surgical instruments designed to sculpt the graft site as taught by the method of the invention.
- The invention further provides for a kit for cartilage and/or chondrocyte transplantation onto the surface of an articular joint wherein said kit comprises a hemostatic barrier, cell-free semi-permeable covering-patch, and organic glue. In a further embodiment, the kit can optionally further provide one or more surgical instruments which can be used to sculpt the graft site in accordance with the methods of the instant invention.
- The present invention further provides an implant for cartilage repair in an animal. In one embodiment, the implant is 1) a support matrix, 2) chondrocyte cells, and 3) a bio-compatible adhesive adhered to an edge of the support matrix. In one embodiment, the support is absorbable by the animal.
- The present invention will be better understood by examining the following figures which illustrate certain properties of the instant invention wherein:
-
FIG. 1A is a drawing showing a typical articulating end of a bone. Typically, the bone material is covered on the articulating surface with a cartilaginous cap (shown by cross-hatching). -
FIG. 1B shows an example of where a defect or injury to the cartilaginous cap occurs (gap in the cross-hatching), and such a defect can be treated directly, enlarged slightly, or sculpted to accept the grafted material by surgical procedures prior to treatment. -
FIG. 1C shows how the hemostatic barrier (solid black, numbered 1) is placed within the defect in the cartilage cap to inhibit or prevent vascularization into regenerating cartilage, from the underlying bone. The chondrocytes to be implanted into the defect cavity are then layered on top of the hemostatic barrier. -
FIG. 2 is a drawing showing the treated defect (gap in cross-hatched area) in the cartilaginous cap (cross-hatched area) covered by a cell-free semi-permeable material (solid black, numbered 2) which is used to form a cap/patch or bandage over the defect site. This cap is fixed in place, either sutured to the edge of the cavity into healthy cartilage, or otherwise attached. This cap is covering the defective area of the joint into which the glue and cultured chondrocytes/cartilage transplant has been placed. -
FIG. 3A is a diagram illustrating the differential response to compression and shearing forces by harder and softer cartilage with subsequent zone of demarcation. -
FIG. 3B illustrates the graft site, after the defect has been sculpted to have undulating walls. -
FIG. 3C illustrates the sculpted graft site with the hemostatic barrier (1), transplanted material (3), and cell-free covering-patch (2) in place within the articular surface cartilage (4). -
FIG. 4A illustrates one embodiment of the surgical device of the instant invention showing cutting teeth (5) and protruding placement pin (6). -
FIG. 4B illustrates a second embodiment of the surgical device of the instant invention. -
FIG. 5 is a diagram illustrating the modified differential response to compression and shearing forces by harder cartilage and softer cartilage after sculpting the graft site. -
FIG. 6A is an MRI image of a pig knee showing cartilage defect in left (medial) condyle. -
FIG. 6B is an MRI image of the same pig knee three months after treatment. -
FIG. 7 illustrates a graft site or defect (23) without a hemostatic barrier, including a mixture of transplanted cells (21) and bio-compatible glue (22) on a support matrix (18) having a porous side, a cartilaginous material and transplanted material interface (30), cartilage (10), a bone material and cartilaginous material interface (12), a resorbable pin (24) and a bone material (14). - This invention concerns the use of certain products that inhibit the formation of vascular tissue, for instance such as capillary loops projecting into the cartilage being established, during the process of autologous transplantation of chondrocytes into defects in the cartilage. The formation of vascular tissue from the underlying bone will tend to project into the new cartilage to be formed leading to appearance of cells other than the mesenchymal specialized chondrocytes desired.
- The contaminating cells introduced by the vascularization may give rise to encroachment and over-growth into the cartilage to be formed by the implanted chondrocytes. One of the types of commercial products which can be used in this invention is Surgicel® (Ethicon Ltd., UK) which is absorbable after a period of 7-14 days. The use of this material in the method of the instant invention is contrary to the normal use of a hemostatic device, such as Surgicel® as it is described in the package insert from Ethicon Ltd.
- Surprisingly, we have found that in a situation where you wish to inhibit re-vascularization into cartilage, a hemostatic material will act like a gel-like artificial coagulate. If red blood cells should be present within the full-thickness defect of articular cartilage that is capped by such a hemostatic barrier, these blood cells will be chemically changed to hematin, and thus rendered unable to induce vascular growth. Thus, a hemostatic product used as a re-vascularization inhibitory barrier with or without fibrin adhesives, such as for example the Surgicel®, is effective for the envisioned method as taught by the instant invention. Another part of this invention is the use of a cell-free component, that is used as a patch covering the defective area of the joint into which the cultured chondrocytes/cartilage are being transplanted, using autologous chondrocytes for the transplantation. The method of the invention also contemplates the use of suitable allogenic chondrocytes or xenogenic chondrocytes for the repair of a cartilage defect.
- Thus the instant invention teaches methods for effective repair or treatment of cartilage defects in articular joint bone surfaces which comprises administering an agent or device to block vascular invasion into the cartilage site to be repaired, and also providing for a cell-free barrier which will isolate the repair site and keep transplanted cells in place. The instant invention also provides for a kit comprising a hemostatic barrier component for insertion into the site to be repaired, such that there is effective inhibition of vascularization into the site to be repaired; and once the chondrocytes to be transplanted are placed into the site to be repaired, a cell-free semi-permeable barrier is capped over the repair site such that the transplanted chondrocytes are held in place, but are still able to gain access to nutrients.
- Certain aspects of the invention have been exemplified using an in vitro system to study the behavior of the chondrocytes when in contact with a certain product or a combination of certain products that inhibit the formation of vascular tissue. This in vitro testing predicts the ability of certain tested materials to inhibit vascularization, as will occur in vivo where capillary loops project into the cartilage being established during the process of autologous transplantation of chondrocytes into defects in the cartilage.
- Suitable hemostatic products will be characterized by having the ability to inhibit the growth, or invasion of vascular tissue, osteocytes, fibroblasts etc. into the developing cartilage. A suitable hemostatic material will achieve the goal of the method of the instant invention in that vascular and cellular invasion into developing cartilage should be prevented in order to optimize the formation of cartilage and achieve repair of the full-thickness of any defects in the articular cartilage. Ideally, the hemostatic barrier will be stable for an extended period of time sufficient to allow for full cartilage repair, and then be able to be resorbed or otherwise broken down over time. One material identified as suitable is called Surgicel® W1912 (an absorbable hemostat containing oxidized regenerated sterile cellulose; Lot GG3DH, Ethicon Ltd. UK). Another example of a suitable material is BioGide® (a commercially available type I collagen matrix pad; Geistlich Sohne, Switzerland).
- Suitable organic glue material can be found commercially, such as for example Tisseel® or Tissucol® (fibrin based adhesive; Immuno AG, Austria), Adhesive Protein (Cat. #A-2707, Sigma Chemical, USA), and Dow Corning Medical Adhesive B (Cat. #895-3, Dow Corning, USA).
- The surgical instruments contemplated by the instant invention can be manufactured from metal and/or plastic suitable for making single-use disposable, or multi-use reusable surgical instruments. The cutting instrument may contain cutting teeth that are fully circular or flat, or anything in between. As cartilage is a relatively soft material it may be advantageous to manufacture hardened plastic cutting edges which will be able to sculpt cartilage without being able to damage bone. Such cutting instruments can be manufactured to incorporate openings for administration of fluid, suction removal of cutting debris and fluid, and fiber optic threads for illumination and visualization of the defect site.
- In another embodiment, the present invention includes
cells 21 andglue 22 combined together as (1) a mixture ofglue 22 andcells 21 or (2) one or more alternating layers ofcells 21 andglue 22 onsupport matrix 18. - In one such embodiment, it is contemplated that
cells 21 are autologous chondrocyte cells to be transplanted into adefect 23.Chondrocytes 21 are mixed, either homogeneously or non-homogeneously, with asuitable glue 22 before application of the chondrocyte/glue mixture to supportmatrix 18. Preferably,glue 22 andchondrocytes 21 are mixed immediately (that is, in the operating theater) before applyingglue 22 andcells 21 to supportmatrix 18, and implantation of the combination ofglue 22,cells 21, andsupport matrix 18 intodefect 23. Alternativelycells 21 andglue 22 are alternately applied in one or more layers to supportmatrix 18. In one embodiment,glue 22 is a bio-compatible glue, such as a fibrin glue, and more specifically either an autologous fibrin glue or a non-autologous fibrin glue. Preferably, an autologous fibrin glue is used. - When
chondrocytes 21 are combined withglue 22 onsupport matrix 23, the glue/chondrocyte/support matrix combination is implanted intodefect 23 either with or without a hemostatic barrier (as described herein) betweenbone 14 and the glue/chondrocyte/support matrix combination. In one embodiment, as shown inFIG. 2 , treateddefect 23 does not contain a hemostatic barrier betweenbone 14 and the glue/chondrocyte/support matrix combination. - In one embodiment, shown in
FIG. 7 , the treatment ofdefect 23 according to the present invention similarly is accomplished without the use of a hemostatic barrier between the glue/chondrocyte/support matrix combination and the base ofdefect 23. - Additionally, in the embodiment shown in
FIG. 7 , the combination ofglue 22 andchrondrocytes 21 is present only on a portion ofsupport matrix 18. For example,glue 22 andchondrocytes 21 preferably are only on an outer edge of a porous side ofsupport matrix 18. Alternatively,chondrocytes 21 and/orglue 22 penetrate into a porous side ofsupport matrix 18 to a desired level, for example 2 to 50% of the depth ofsupport matrix 18. Typically the porosity ofsupport matrix 18 is greatest nearest a rough side, i.e., the side on whichcells 21 andglue 22 are deposited, and least porous on the opposite side ofsupport matrix 18. As further illustrated byFIG. 7 , the porosity ofsupport matrix 18 is indicated by shading, where the darker shading indicates less porosity, and the lighter shading indicates greater porosity. - In yet another embodiment,
chondrocytes 21 are applied to supportmatrix 18, then covered with a layer of a suitablebio-compatible glue 22. Although a single layer ofchondrocytes 21 onsupport matrix 18 and a single layer ofglue 22 positioned overchondrocytes 21 is sufficient for effective treatment of a defect, more than one alternating layer ofglue 22 andchondrocytes 21 can be used. Alternatively, a layer ofbio-compatible glue 22 can be initially deposited onsupport matrix 18, followed by a layer ofchondrocytes 21 deposited onglue 22. - In one embodiment,
support matrix 18 is a sheet-like member capable of supporting growth ofchondrocytes 21 and of providing physical integrity to the implantable article to facilitate manipulation thereof. In an embodiment,support matrix 18 includes polypeptides or proteins such as collagen. In particular,support matrix 18 includes equine, porcine, bovine, ovine and chicken collagen. Additionally, the collagen can be either Type I or Type II collagen. Examples of appropriatecollagen support matrices 18 include ChondraGide® and BioGide® (commercially available type I collagen matrix pads; available from Geistlich Sohne, Switzerland). Additionally,support matrix 18 is reversibly deformable and has either a rough side that is porous, as described above, or a smooth side, or two rough sides. Although either side can be porous, in one embodiment as described herein, the rough side has greater porosity relative to the smooth side.Support matrix 18 andcells 21 positioned thereon can be optionally held in place in the defect by additionalbio-compatible glue 22 and/or one or more biocompatibleresorbable pins 24, as shown inFIG. 7 . - In one embodiment, one or more portions of
support matrix 18 is either solid or gel-like in character. - Certain aspects of the instant invention may be better understood as illustrated by the following examples, which are meant by way of illustration and not limitation.
- In order for the Surgicel® to be used according to the invention for preventing development of blood vessels into autologous implanted cartilage or chondrocytes, Surgicel® was first treated with a fixative, such as glutaric aldehyde. Briefly, Surgicel® was treated with 0.6% glutaric aldehyde for 1 minute, followed by several washings to eliminate glutaric aldehyde residues that may otherwise be toxic to tissue. Alternatively, the Surgicel® was treated with the fibrin adhesive called Tisseel® prior to treatment with glutaric aldehyde as described in Example 2. It was found that the Surgicel® fixated for instance with a fixative such as glutaric aldehyde, washed with sterile physiological saline (0.9%) and stored in refrigerator, does not dissolve for 1 to 2 months. Generally, Surgicel® is resorbed in a period between 7 and 14 days. This time would be too short, because a longer time is needed in preventing the development of blood vessels or vascularization as such from the bone structure into the implanted cartilage before the implanted chondrocytes have grown into a solid cartilage layer getting its nutrition requirements from the neighboring cartilage. In other words sufficient inhibition of the vascularization is needed for a longer time, such as for instance one month. Therefore, the product should not be absorbed significantly prior to that time. On the other hand resorption is needed eventually. Hence, the organic material used as an inhibiting barrier shall have these capabilities, and it has been found that the Surgicel® treated in this manner provides that function.
- The Surgicel® was also coated with an organic glue, in this example the glue used was Tisseel® but others can also be used. This product, together with the Surgicel® produces a useable barrier for the particular purpose of the invention. Any other hemostat or vascular inhibiting barrier could be used. The Tisseel® was mixed as described below. The Surgicel® was then coated with Tisseel® by spraying the Surgicel® material on both sides until soaked. The Tisseel® (fibrin glue) was then allowed to solidify at room temperature. Immediately prior to completed solidification, the coated Surgicel® was then placed in 0.6% glutaric aldehyde for 1 minute and then washed with sterile physiological (0.9%) saline. The pH was then adjusted by PBS and/or with NaOH until pH was stable at 7.2 to 7.4. Afterwards the thus treated Surgicel® was then washed in tissue culture medium such as minimum essential medium/F12 with 15 mM Hepes buffer.
- As mentioned in this example we have used Tisseel® as the fibrin adhesive to coat the Surgicel®. Furthermore the fibrin adhesive or glue may also be applied directly on the bottom of the lesion towards the bone, on which the Surgicel® is glued. The in vitro system used, in lieu of in vivo testing, consisted of a NUNCLON™ Delta 6-well sterile disposable plate for cell research work (NUNC. InterMed, Roskilde, Denmark). Each well measures approximately 4 cm in diameter.
- In the invention the fibrin adhesive can be any adhesive which together with the fibrin component will produce a glue that can be tolerated in humans (Ihara, N, et al., Burns Incl. Therm. Inj., 1984, 10, 396). The invention also anticipates any other glue component that can be used in lieu of the fibrin adhesive. In this invention we used Tisseel® or Tissucol® (Immuno AG, Vienna, Austria). The Tisseel® kit consists of the following components:
-
- Tisseel®, a lyophilized, virus-inactivated Sealer, containing clottable protein, thereof: fibrinogen, Plasma fibronectin (CIG) and Factor XIII, and Plasminogen;
- Aprotinin Solution (bovine);
- Thrombin 4 (bovine);
- Thrombin 500 (bovine); and
- Calcium Chloride solution.
- The Tisseel® kit contains a DUPLOJECT® Application System. The fibrin adhesive or the two-component sealant using Tisseel® Kit is combined in the following manner according to the Immuno AG product insert sheet.
- Chondrocytes were grown in minimal essential culture medium containing HAM F12 and 15 mM Hepes buffer and 5 to 7.5% autologous serum in a CO2 incubator at 37° C. and handled in a Class 100 laboratory at Verigen Europe A/S, Symbion Science Park, Copenhagen, Denmark. Other compositions of culture medium may be used for culturing the chondrocytes. The cells were trypsinized using trypsin EDTA for 5 to 10 minutes and counted using Trypan Blue viability staining in a Burker-Turk chamber. The cell count was adjusted to 7.5×105 cells per ml. One NUNCLON™ plate was uncovered in the Class 100 laboratory.
- The Surgicel® hemostatic barrier was cut to a suitable size fitting into the bottom of the well in the NUNCLON™ tissue culture tray. In this case a circle, of a size of approximately 4 cm (but could be of any possible size) and placed under aseptic conditions on the bottom in well in a NUNCLON™ Delta 6-well sterile disposable plate for cell research work (NUNC, InterMed, Roskilde, Denmark). The hemostatic barrier to be placed on the bottom of the well was pre-treated as described in Example 1. This treatment delays the absorption of the Surgicel significantly. This hemostatic barrier was then washed several times in distilled water and subsequently several times until non-reacted glutaraldehyde was washed out. A small amount of the cell culture medium containing serum was applied to be absorbed into the hemostatic barrier and at the same time keeping the hemostatic barrier wet at the bottom of the well.
- Approximately 106 cells in 1 ml culture medium were placed directly on top of the hemostatic barrier, dispersed over the surface of the hemostatic barrier pre-treated with 0.4% glutaraldehyde as described above. The plate was then incubated in a CO2 incubator at 37° C. for 60 minutes. An amount of 2 to 5 ml of tissue culture medium containing 5 to 7.5% serum was carefully added to the well containing the cells avoiding splashing the cells by holding the pipette tip tangential to the side of the well when expelling the medium. It appeared that the pH of the medium was too low (pH ˜6.8). The pH was then adjusted to 7.4 to 7.5. The next day some chondrocytes had started to grow on the hemostatic barrier, arranged in clusters. Some of the cells had died due to the low pH exposure prior to the adjustment of the pH. The plate was incubated for 3 to 7 days with medium change at
day 3. - At the end of the incubation period the medium was decanted, and cold refrigerated 2.5% glutaraldehyde containing 0.1M sodium salt of dimethylarsinic acid, (also called sodium cacodylate, pH is adjusted with HCl to 7.4), was added as a fixative for preparation of the cell and supporter (hemostatic barrier) for later preparation for electron microscopy.
- Chondrocytes were grown in minimal essential culture medium containing HAM F12 and 15 mM Hepes buffer and 5 to 7.5% autologous serum in a CO2 incubator at 37 C. and handled in a Class 100 laboratory at Verigen Europe A/S, Symbion Science Park, Copenhagen, Denmark. Other compositions of culture medium may be used for culturing the chondrocytes. The cells were trypsinized using trypsin EDTA for 5 to 10 minutes and counted using Trypan Blue viability staining in a Burker-Turk chamber. The cell count was adjusted to 7.5×105 cells per ml. One NUNCLON™ plate was uncovered in the Class 100 laboratory.
- The Surgicel® (for use as the hemostatic barrier) was treated with 0.6% glutaric aldehyde for one minute as described in Example 1, and washed with 0.9% sterile sodium chloride solution or, preferably, with a buffer such as a PBS buffer or the culture medium such as MEM/F12, because the pH after the glutaric aldehyde treatment is 6.8 and should preferably be 7.0 to 7.5. The Tisseel® was applied on both sides of the Surgicel® using the DUPLOJECT® system, thus coating both sides of the Surgicel®, the patch intended to be used, with fibrin adhesive. The glue is left to dry under aseptic condition for at least 3 to 5 minutes. The “coated” hemostatic barrier was placed on the bottom of the well in a NUNCLO™ Delta 6-well sterile disposable plate for cell research work. A small amount of tissue culture medium containing serum was applied to be absorbed into the hemostatic barrier. Approximately 106 cells in 1 ml tissue culture medium containing serum was placed directly on top of the Hemostat, dispersed over the surface of the hemostatic barrier. The plate was then incubated in a CO2 incubator at 37° C. for 60 minutes. An amount of 2 to 5 ml of tissue culture medium containing 5 to 7.5% serum was carefully added to the well containing the cells avoiding splashing the cells by holding the pipette tip tangential to the side of the well when expelling the medium. After 3 to 6 days, microscopic examination showed that the cells were adhering to and growing into the Surgicel® in a satisfactory way suggesting that Surgicel® did not show toxicity to the chondrocytes and that the chondrocytes grew in a satisfactory manner into the Surgicel®.
- The plate was incubated for 3 to 7 days with medium change at
day 3. At the end of the incubation period the medium was decanted, and cold refrigerated, and 2.5% glutaraldehyde containing 0.1M sodium salt of dimethylarsinic acid, also called sodium cacodylate, pH is adjusted with HCl to 7.4, was added as a fixative for preparation of the cell and supporter (hemostatic barrier) for later preparation for electron microscopy. - Chondrocytes were grown in minimal essential culture medium containing HAM F12 and 15 mM Hepes buffer and 5 to 7.5% autologous serum in a CO2 incubator at 37 C. and handled in a Class 100 laboratory at Verigen Europe A/S, Symbion Science Park, Copenhagen, Denmark. The cells were trypsinized using trypsin EDTA for 5 to 10 minutes and counted using Trypan Blue viability staining in a Burker-Turk chamber. The cell count was adjusted to 7.5×105 to 2×106 cells per ml. One NUNCLON™ plate was uncovered in the Class 100 laboratory.
- It has been found that the Bio-Gide® can be used as a resorbable bilayer membrane which will be used as the patch or bandage covering the defective area of the joint into which the cultured chondrocytes are being transplanted as well as the hemostatic barrier. The Bio-Gide® is a pure collagen membrane obtained by standardized, controlled manufacturing processes (by E. D. Geistlich Sohne AG, CH-6110 Wolhusen). The collagen is extracted from veterinary certified pigs and is carefully purified to avoid antigenic reactions, and sterilized in double blisters by gamma irradiation. The bilayer membrane has a porous surface and a dense surface. The membrane is made of collagen type I and type III without further cross-linking or chemical treatment. The collagen is resorbed within 24 weeks. The membrane retains its structural integrity even when wet and it can be fixed by sutures or nails. The membrane may also be “glued” using fibrin adhesive such as Tisseel® to the neighboring cartilage or tissue either instead of sutures or together with sutures.
- The Bio-Gide® was un-covered in a class 100 laboratory and placed under aseptic conditions on the bottom of the wells in a NUNCLON™ Delta 6-well sterile disposable plate for cell research work,—either with the porous surface of the bilayer membrane facing up or with the dense surface facing up. Approximately 106 cells in 1 ml tissue culture medium containing serum was placed directly on top of the Bio-Gide®, dispersed either over the porous or the dense surface of the Bio-Gide®. The plate was then incubated in a CO2 incubator at 37° C. for 60 minutes. An amount of 2 to 5 ml of tissue culture medium containing 5 to 7.5% serum was carefully added to the well containing the cells avoiding splashing the cells by holding the pipette tip tangential to the side of the well when expelling the medium.
- On
day 2 after the chondrocytes were placed in the well containing the Bio-Gide® the cells were examined in a Nikon Inverted microscope. It was noticed that some chondrocytes had adhered to the edge of the Bio-Gid®. It was of course not possible to look through the Bio-Gide® itself using this microscope. - The plate was incubated for 3 to 7 days with medium change at
day 3. At the end of the incubation period the medium was decanted, and cold refrigerated 2.5% glutaraldehyde containing 0.1M sodium salt of dimethylarsinic acid, also called sodium cacodylate, pH is adjusted with HCl to 7.4, was added as fixative for preparation of the cell and the Bio-Gide® supporter with the cells either cultured on the porous surface or the dense surface. The Bio-Gide® patches were then sent for electron microscopy at Department of Pathology, Herlev Hospital, Denmark. - The electron microscopy showed that the chondrocytes cultured on the dense surface of the Bio-Gide® did not grow into the collagen structure of the Bio-Gide®, whereas the cells cultured on the porous surface did indeed grow into the collagen structure and furthermore, showed presence of proteoglycans and no signs of fibroblast structures. This result shows that when the collagen patch, as for instance a Bio-Gide® patch is sewn as a patch covering a cartilage defect the porous surface shall be facing down towards the defect in which the cultured chondrocytes are to be injected. They will then be able to penetrate the collagen and produce a smooth cartilage surface in line with the intact surface, and in this area a smooth layer of proteoglycans will be built up. Whereas, if the dense surface of the collagen is facing down into the defect the chondrocytes to be implanted will not integrate with the collagen, and the cells will not produce the same smooth surface as described above.
- Chondrocytes were grown in minimal essential culture medium containing HAM F12 and 15 mM Hepes buffer and 5 to 7.5% autologous serum in a CO2 incubator at 37° C. and handled in a Class 100 laboratory at Verigen Europe A/S, Symbion Science Park, Copenhagen, Denmark. The cells were trypsinized using trypsin EDTA for 5 to 10 minutes and counted using Trypan Blue viability staining in a Burker-Turk chamber. The cell count was adjusted to 7.5×106 to 2×106 cells per ml. One NUNCLON™ plate was uncovered in the Class 100 laboratory.
- The Bio-Gide® used as a resorbable bilayer membrane may also be used together with an organic glue such as Tisseel® with additional, significantly higher content of Aprotinin than normally found in Tisseel®, as described in the product insert. By increasing the content of Aprotinin to about 25,000 KIU/ml, the resorption of the material will be delayed by weeks instead of the normal span of days.
- To test this feature in vitro, the Tisseel® is applied to the bottom of the well of the NUNCLON™ plate, and allowed to solidify incompletely. A collagen patch such as a Bio-Gide® is then applied over the Tisseel® and glued to the bottom of the well. This combination of Bio-Gide® and Tisseel® is designed to be a hemostatic barrier that will inhibit or prevent development or infiltration of blood vessels into the chondrocyte transplantation area. This hybrid collagen patch can now be used for both a hemostatic barrier at the bottom of the lesion (most proximal to the surface to be repaired) as well as a support for cartilage formation because the distal surface can be the porous side of the collagen patch and thus encourage infiltration of chondrocytes and cartilage matrix. Thus, this hybrid collagen patch can also be used to cover the top of the implant with the collagen porous surface directed down towards the implanted chondrocytes and the barrier forming the top. The hybrid collagen patch, with elevated Aprotinin component may also be used without any organic glue such as Tisseel® and placed within the defect directly, adhering by natural forces. Thus the collagen patch can be used both as the hemostatic barrier, and the cell-free covering of the repair/transplant site, with the porous surfaces of the patches oriented towards the transplanted chondrocytes/cartilage. Another variant would use a collagen patch which consists of type II collagen (i.e. from Geistlich Sohne AG, CH-6110 Wolhusen).
- Thus the instant invention provides for a hybrid collagen patch where said patch is a collagen matrix with elevated levels of aprotinin component, preferably about 25,000 KIU/ml, in association with an organic matrix glue, where the collagen component is similar to the Bio-Gide® resorbable bilayer material or Type II collagen, and the organic glue is similar to the Tisseel® material. In another embodiment, the hybrid collagen patch does not use any organic glue to adhere to the site of the repair.
- Because of the weakened structure of osteoarthritic cartilage, adherence of cultured autologous chondrocytes transplanted to a graft site in defective cartilage may be inhibited, thus creating a marginal zone (zone of demarcation) between the newly implanted cartilage/chondrocytes and the surrounding established cartilage. This marginal zone will be most pronounced if the graft site is prepared for the graft by creating straight, smooth walls cut in a linear fashion. The shearing and compression forces across such a marginal zone (as illustrated in
FIG. 3A ) will exert great force to dislodge the graft when the graft site is cut in a linear fashion. This marginal zone, and differential movement of materials along this zone will inhibit confluent healing between the grafted material and the surrounding material. In many cases the graft material is softer than the surrounding material, however, in some instances of osteoarthritis disease, the surrounding cartilage may in fact be softer than the implanted chondrocytes/cartilage. - Therefore, in order to solve this problem, the method of the invention teaches the use of surgical instruments to sculpt the walls of the graft site such that the walls are non-linear, and thus provide for undulated surfaces. It is also possible to shape the graft site such that the diameter of the site proximal to the bone surface is of a greater dimension then the opening distal to the bone, and at the surface of the cartilage. However, the preferred embodiment describes the sculpting of the walls of the graft site in an fashion similar to a threaded opening for receiving a bolt or screw (as illustrated in
FIG. 3B ), thus providing mechanical resistance to the compression and or ejection of the grafted material from the graft site which can be described as “male” and “female” threading. - The surgical instruments contemplated by the instant invention can be manufactured from metal and/or plastic suitable for making single-use disposable, or multi-use reusable surgical instruments. As cartilage is a relatively soft material it may be advantageous to manufacture hardened plastic cutting edges which will be able to sculpt cartilage without being able to damage bone. Such cutting instruments can be manufactured to incorporate openings for administration of fluid, suction removal of cutting debris and fluid, and fiber optic threads for illumination and visualization of the defect site. In certain embodiments of the instrument, the base of the instrument may have protruding point or pin-like structure which will assist in guiding and placing the instrument in the graft site. Of course such a pin would be designed to minimized damage to the underlying bone.
- While the cutting surface of the instrument may be single toothed, or multi-toothed, or describe a screw-like pattern such as that in a metal tap used to generate threaded holes in metal parts, the characteristic required of the cutting instrument is that the resulting sculpted sides of the graft site is undulated, and non-linear. For example, in certain embodiments, the cutting edge of the instrument can be shaped similar to that shown in
FIG. 4A , or as inFIG. 4B . The cutting edge maybe flat, or circular in that it wraps around the diameter of the cutting instrument. Many other shapes can be designed to accomplish the purpose of the method of the invention to create an interface which provides for mechanical resistance to differential reaction to compression and shearing forces on the transplanted material and the surrounding material. - A four month old mixed Yorkshire breed pig was subjected to general anesthesia and placed on its back. The pig was washed and draped in a surgical suite at Harrington Arthritis Research Center, Phoenix, Ariz. The entire surgical procedure was performed aseptically. The left hind-leg and adjacent abdomen and inguinal area was cleaned with iodine. The knee joint was localized, and the patella localized. A medial incision was performed approximately 3 cm from the posterior part of the patella and the several subcutis, muscle layers and ligaments was cut approximately in order to get access to the medial femoral condyle. Using a circular cutter a lesion was prepared in the white cartilage on the medial part of the medial condyle, leaving a 0.5 to 1 cm margin to the edge of the cartilage covering the posterior-medial part of the condyle (left condyle,
FIG. 6A ). The 0.5 to 1 cm defect was placed in a caudal weight bearing part of the medial condyle. The entire surgical procedure was done without tourniquet on the left femur. The different layers and skin was sutured appropriately. - On
day 3 the animal was again brought to the surgical suite and positioned as above on the operating table and given general anesthesia. The left hind leg, abdomen and inguinal region was cleaned with iodine, as described above. Sutures were cut and the area opened. It was noticed that a moderate hematoma was present in the knee joint. The blood clot was removed and the defect inspected. There was a blood clot in the defect which was removed. A sterile surgical instrument designed with a male thread cutting edge, with a size corresponding to, or slightly bigger than the circumference of the lesion was carefully screwed down into the defect. A BioGide® pad was cut to a size equal to the bottom of the defect. The first glue used, called Adhesive Protein (A-2707, Sigma Chemical, USA) was applied on the dense side of the trimmed hemostatic barrier pad, and the pad was placed dense side down into the bottom of the lesion, using it as a barrier as described above. It was found that this glue did not seem to dry very fast. The slight bleeding from the bottom of the defect stopped immediately. A second BioGide® was cut somewhat bigger in circumference than the lesion and was placed with dense side up (thus the porous side down towards the graft) as described above. - This non-cellular covering-pad was then sutured over the cavity, leaving one edge open, where the chondrocyte to be explanted could be injected. The surrounding part of the edge of the pad was covered with the second glue, Dow Corning Medical Adhesive B (Cat. #895-3, Dow Corning, USA). This second glue dried much faster and more efficiently than the first glue. It was found that during this particular procedure, the first glue had not dried sufficiently to hold the hemostatic barrier in place when suturing of the cap was attempted. Thus, the main barrier formed on the proximal surface of the graft site was by the glue itself.
- Using a 1 ml syringe and a 16 gauge needle, the chondrocyte cell suspension (about 0.6 ml) was drawn up into the barrel of the syringe. A 23 gauge short needle was switched for the 16 gauge needle, and the cell suspension was injected under the sutured covering-patch into the graft site (about 10×106 cells). The open edge of the cap was then glued prior to removal of the needle, and the needle carefully withdrawn. No leakage of cells was seen. The wound was sutured and as above, no tourniquet was used, no bleeding was observed. The final skin layers were sutured. No protrusion of the skin occurred after suturing, which indicates that there was no hematoma. Postoperative recovery was uneventful.
- As expected, the grafted chondrocytes produced cartilage matrix sufficient to repair the defect made in the articular cartilage surface of the knee joint of the test pig.
FIG. 6A is an MRI image of a pig knee showing the cartilage defect created in the knee (left condyle, the medial condyle), andFIG. 6B is an MRI image of the same pig knee three months after treatment showing repair of the defect. - A kit comprising the components useful for practicing the method of the invention, will allow for the convenient practice of the method of the invention in a surgical setting. In a preferred embodiment, a kit of the invention will provide sterile components suitable for easy use in the surgical environment, and will provide a suitable hemostatic barrier, suitable covering patch, and if needed organic glue. A kit of the invention may also provide sterile, cell-free matrix material suitable for supporting autologous chondrocytes that are to be implanted into an articular joint surface defect. In one embodiment, a kit of the invention contains a Surgicel® hemostatic barrier and a Bio-Gide® covering patch with suitable coating of Tisseel® organic glue, where the Surgicel® and Bio-Gide® have been treated according to the teachings of the invention to increase the time till resorption. In instances where Tisseel® is pre-coated, in one embodiment the Tisseel® is supplemented with additional aprotinin to increase time till resorption.
- In another preferred embodiment, the hemostatic barrier and covering-patch are both a semi-permeable collagen matrix which is treated to extend the time till resorption of the material. It is also possible to provide Tisseel® glue in enhanced form as a separate component to be applied as needed because of the inherent variability and unique circumstances every repair/transplantation procedure will encounter.
- A further embodiment of the kit will include a surgical instrument as described in Example 7 above.
- It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention shown in the specific embodiments without departing form the spirit and scope of the invention as broadly described.
Claims (15)
1. An implantable article for cartilage repair by implantation in an animal comprising a support matrix, and chondrocyte cells and a bio-compatible adhesive adhered to an edge of said support matrix, wherein said support matrix is absorbable by the animal.
2. The implantable article of claim 1 , wherein said support matrix is a sheet-like member capable of supporting growth of the chondrocyte cells and of providing physical integrity to the implantable article to facilitate manipulation thereof.
3. The implantable article of claim 1 , wherein said support matrix comprises polypeptides or proteins.
4. The implantable article of claim 1 , wherein said support matrix is collagen.
5. The implantable article of claim 1 , wherein said collagen is selected from the group consisting essentially of equine, porcine, bovine, ovine and chicken collagen.
6. The implantable article of claim 1 , wherein said support matrix is solid.
7. The implantable article of claim 1 , wherein said support matrix is gel-like.
8. The implantable article of claim 4 , wherein said collagen is collagen Type I.
9. The implantable article of claim 4 , wherein said collagen is collagen Type II.
10. The implantable article of claim 1 , wherein said implantable article is reversibly deformable.
11. The implantable article of claim 1 , wherein said support matrix has a rough side.
12. The implantable article of claim 11 , wherein said rough side is porous.
13. The implantable article of claim 1 , wherein said support matrix has a smooth side.
14. The implantable article of claim 1 , wherein said support matrix has a rough and a smooth side.
15. The implantable article of claim 1 , wherein said chondrocyte cells and said bio-compatible adhesive are in an admixture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/375,183 US20060167483A1 (en) | 1996-08-30 | 2006-03-14 | Method, instruments, and kit for autologous transplantation |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/704,891 US5759190A (en) | 1996-08-30 | 1996-08-30 | Method and kit for autologous transplantation |
US08/857,090 US5989269A (en) | 1996-08-30 | 1997-05-15 | Method, instruments and kit for autologous transplantation |
US09/320,246 US6283980B1 (en) | 1996-08-30 | 1999-05-26 | Method, instruments, and kit for autologous transplantation |
US09/690,252 US6379367B1 (en) | 1996-08-30 | 2000-10-17 | Method instruments and kit for autologous transplantation |
US09/970,323 US6569172B2 (en) | 1996-08-30 | 2001-10-03 | Method, instruments, and kit for autologous transplantation |
US10/397,404 US7137989B2 (en) | 1996-08-30 | 2003-03-26 | Method, instruments, and kit for autologous transplantation |
US11/375,183 US20060167483A1 (en) | 1996-08-30 | 2006-03-14 | Method, instruments, and kit for autologous transplantation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/397,404 Continuation US7137989B2 (en) | 1996-08-30 | 2003-03-26 | Method, instruments, and kit for autologous transplantation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060167483A1 true US20060167483A1 (en) | 2006-07-27 |
Family
ID=25516762
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/970,323 Expired - Fee Related US6569172B2 (en) | 1996-08-30 | 2001-10-03 | Method, instruments, and kit for autologous transplantation |
US10/397,404 Expired - Fee Related US7137989B2 (en) | 1996-08-30 | 2003-03-26 | Method, instruments, and kit for autologous transplantation |
US11/375,183 Abandoned US20060167483A1 (en) | 1996-08-30 | 2006-03-14 | Method, instruments, and kit for autologous transplantation |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/970,323 Expired - Fee Related US6569172B2 (en) | 1996-08-30 | 2001-10-03 | Method, instruments, and kit for autologous transplantation |
US10/397,404 Expired - Fee Related US7137989B2 (en) | 1996-08-30 | 2003-03-26 | Method, instruments, and kit for autologous transplantation |
Country Status (16)
Country | Link |
---|---|
US (3) | US6569172B2 (en) |
EP (1) | EP1437969B1 (en) |
JP (1) | JP2005504576A (en) |
CN (1) | CN1612715A (en) |
AT (1) | ATE499887T1 (en) |
AU (1) | AU2002334852B2 (en) |
BR (1) | BR0213114A (en) |
CA (1) | CA2462306A1 (en) |
DE (1) | DE60239351D1 (en) |
DK (1) | DK1437969T3 (en) |
HK (1) | HK1064021A1 (en) |
IL (1) | IL161152A0 (en) |
MX (1) | MXPA04003177A (en) |
PL (1) | PL210783B1 (en) |
RU (1) | RU2004113440A (en) |
WO (1) | WO2003028545A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090234452A1 (en) * | 2008-03-06 | 2009-09-17 | Steiner Anton J | Instrumentation and method for repair of meniscus tissue |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
USRE42208E1 (en) | 2003-04-29 | 2011-03-08 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US8292968B2 (en) | 2004-10-12 | 2012-10-23 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
US20130226185A1 (en) * | 2000-01-14 | 2013-08-29 | Bonutti Skeletal Innovations Llc | Femoral guide for knee surgery |
US8784495B2 (en) | 2000-01-14 | 2014-07-22 | Bonutti Skeletal Innovations Llc | Segmental knee arthroplasty |
US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8735773B2 (en) | 2007-02-14 | 2014-05-27 | Conformis, Inc. | Implant device and method for manufacture |
US8545569B2 (en) | 2001-05-25 | 2013-10-01 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US7534263B2 (en) | 2001-05-25 | 2009-05-19 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
US8480754B2 (en) | 2001-05-25 | 2013-07-09 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US8771365B2 (en) | 2009-02-25 | 2014-07-08 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs, and related tools |
US8556983B2 (en) | 2001-05-25 | 2013-10-15 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
US7468075B2 (en) | 2001-05-25 | 2008-12-23 | Conformis, Inc. | Methods and compositions for articular repair |
US9603711B2 (en) | 2001-05-25 | 2017-03-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
US8083745B2 (en) | 2001-05-25 | 2011-12-27 | Conformis, Inc. | Surgical tools for arthroplasty |
US7618451B2 (en) | 2001-05-25 | 2009-11-17 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty |
US9289153B2 (en) * | 1998-09-14 | 2016-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Joint and cartilage diagnosis, assessment and modeling |
AU772012B2 (en) | 1998-09-14 | 2004-04-08 | Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and preventing damage |
US7239908B1 (en) | 1998-09-14 | 2007-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
US6179840B1 (en) | 1999-07-23 | 2001-01-30 | Ethicon, Inc. | Graft fixation device and method |
US20020095157A1 (en) | 1999-07-23 | 2002-07-18 | Bowman Steven M. | Graft fixation device combination |
DE60138116D1 (en) | 2000-09-14 | 2009-05-07 | Univ R | ASSESSMENT OF THE CONDITION OF A JOINT AND PLANNING OF A TREATMENT |
ATE413135T1 (en) | 2000-09-14 | 2008-11-15 | Univ Leland Stanford Junior | ASSESSMENT OF THE CONDITION OF A JOINT AND THE LOSS OF CARTILAGE TISSUE |
CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US9308091B2 (en) | 2001-05-25 | 2016-04-12 | Conformis, Inc. | Devices and methods for treatment of facet and other joints |
EP1389980B1 (en) | 2001-05-25 | 2011-04-06 | Conformis, Inc. | Methods and compositions for articular resurfacing |
US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
US8439926B2 (en) | 2001-05-25 | 2013-05-14 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
MXPA04005940A (en) * | 2002-01-22 | 2004-09-13 | Pfizer | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases. |
SE0201479D0 (en) * | 2002-05-16 | 2002-05-16 | Pharmacia Groningen Bv | Kit and method in eye surgery |
US20040136968A1 (en) * | 2002-09-27 | 2004-07-15 | Verigen Ag | Autologous cells on a support matrix for tissue repair |
EP1555962B1 (en) * | 2002-10-07 | 2011-02-09 | Conformis, Inc. | Minimally invasive joint implant with 3-dimensional geometry matching the articular surfaces |
US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
US7824701B2 (en) | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
EP1555963A4 (en) | 2002-10-23 | 2008-12-31 | Mako Surgical Corp | Modular femoral component for a total knee joint replacement for minimally invasive implantation |
AU2003290757A1 (en) | 2002-11-07 | 2004-06-03 | Conformis, Inc. | Methods for determing meniscal size and shape and for devising treatment |
US8197837B2 (en) | 2003-03-07 | 2012-06-12 | Depuy Mitek, Inc. | Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof |
US7488348B2 (en) * | 2003-05-16 | 2009-02-10 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US8226715B2 (en) | 2003-06-30 | 2012-07-24 | Depuy Mitek, Inc. | Scaffold for connective tissue repair |
CN1820194B (en) * | 2003-07-30 | 2012-06-13 | 应用材料以色列公司 | Scanning electron microscope having multiple detectors and a method for multiple detector based imaging |
US10583220B2 (en) * | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
US7316822B2 (en) * | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
US7901461B2 (en) | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
EP1576957A1 (en) | 2004-03-18 | 2005-09-21 | Universiteit Twente | Tissue repair using pluripotent cells |
US8137686B2 (en) * | 2004-04-20 | 2012-03-20 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US8221780B2 (en) * | 2004-04-20 | 2012-07-17 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US7335508B2 (en) * | 2004-07-22 | 2008-02-26 | Prochon Biotech Ltd. | Porous plasma protein matrices and methods for preparation thereof |
US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
US20060111778A1 (en) * | 2004-10-29 | 2006-05-25 | Michalow Alexander E | Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway |
US20090214614A1 (en) * | 2005-09-02 | 2009-08-27 | Interface Biotech A/S | Method for Cell Implantation |
EP1764117A1 (en) * | 2005-09-20 | 2007-03-21 | Zimmer GmbH | Implant for the repair of a cartilage defect and method for manufacturing the implant |
US8623026B2 (en) | 2006-02-06 | 2014-01-07 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
EP1981409B1 (en) | 2006-02-06 | 2017-01-11 | ConforMIS, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
NZ571913A (en) * | 2006-03-23 | 2011-11-25 | Univ Western Australia | Tenocyte cell culturing method |
PT2097116E (en) * | 2006-12-22 | 2012-12-06 | Medidom Lab | In situ system for intra-articular chondral and osseous tissue repair |
EP2114312B1 (en) | 2007-02-14 | 2014-01-08 | ConforMIS, Inc. | Method for manufacture of an implant device |
US7758643B2 (en) * | 2007-02-26 | 2010-07-20 | Biomet Sports Medicine, Llc | Stable cartilage defect repair plug |
CN101795718B (en) * | 2007-04-24 | 2013-06-12 | 西澳大利亚大学 | Tenocyte containing bioscaffolds and treatment using the same |
CN102123745A (en) | 2008-02-29 | 2011-07-13 | 科洛普拉斯特公司 | Compositions and methods for augmentation and regeneration of living tissue in a subject |
US8682052B2 (en) | 2008-03-05 | 2014-03-25 | Conformis, Inc. | Implants for altering wear patterns of articular surfaces |
CA2751460A1 (en) * | 2009-02-04 | 2010-08-12 | Massachusetts Institute Of Technology | Compositions and uses to govern cancer cell growth |
US8808297B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US8808303B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
EP2405865B1 (en) | 2009-02-24 | 2019-04-17 | ConforMIS, Inc. | Automated systems for manufacturing patient-specific orthopedic implants and instrumentation |
US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US20120301507A1 (en) | 2009-03-27 | 2012-11-29 | Orthocell Pty Ltd | Method of tissue repair |
BRPI1014917A2 (en) | 2009-04-16 | 2016-04-19 | Conformis Inc | "Patient specific joint arthroplasty devices for ligament repair" |
CA2782137A1 (en) | 2009-12-11 | 2011-06-16 | Conformis, Inc. | Patient-specific and patient-engineered orthopedic implants |
EP2754419B1 (en) | 2011-02-15 | 2024-02-07 | ConforMIS, Inc. | Patient-adapted and improved orthopedic implants |
US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
US9186053B2 (en) * | 2012-05-03 | 2015-11-17 | Covidien Lp | Methods of using light to repair hernia defects |
US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
BR112015000670A2 (en) | 2012-07-11 | 2017-06-27 | Osiris Therapeutics Inc | cartilage product manufacturing methods |
US10016527B2 (en) | 2012-10-23 | 2018-07-10 | Orthovita, Inc. | Materials and methods for repair of cartilage defects |
Citations (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4385404A (en) * | 1980-02-21 | 1983-05-31 | J. & P. Coats, Limited | Device and method for use in the treatment of damaged articular surfaces of human joints |
US4393874A (en) * | 1982-04-26 | 1983-07-19 | Telectronics Pty. Ltd. | Bradycardia event counting and reporting pacer |
US4553272A (en) * | 1981-02-26 | 1985-11-19 | University Of Pittsburgh | Regeneration of living tissues by growth of isolated cells in porous implant and product thereof |
US4559936A (en) * | 1983-09-29 | 1985-12-24 | Hill Edward B | Bone plugging apparatus |
US4642120A (en) * | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
US4642117A (en) * | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
US4649918A (en) * | 1980-09-03 | 1987-03-17 | Custom Medical Devices, Inc. | Bone core removing tool |
US4681588A (en) * | 1983-10-20 | 1987-07-21 | Vettivetpillai Ketharanathan | Biomaterial |
US4789663A (en) * | 1984-07-06 | 1988-12-06 | Collagen Corporation | Methods of bone repair using collagen |
US4846835A (en) * | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
US4877020A (en) * | 1984-11-30 | 1989-10-31 | Vich Jose M O | Apparatus for bone graft |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
US5019108A (en) * | 1990-02-02 | 1991-05-28 | Bertin Kim C | Modular implant |
US5041138A (en) * | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
US5062845A (en) * | 1989-05-10 | 1991-11-05 | Spine-Tech, Inc. | Method of making an intervertebral reamer |
US5067964A (en) * | 1989-12-13 | 1991-11-26 | Stryker Corporation | Articular surface repair |
US5092883A (en) * | 1988-12-28 | 1992-03-03 | Eppley Barry L | Method for promoting soft connective tissue growth and repair in mammals |
US5116374A (en) * | 1989-03-02 | 1992-05-26 | Regen Corporation | Prosthetic meniscus |
US5158574A (en) * | 1987-07-20 | 1992-10-27 | Regen Corporation | Prosthetic meniscus |
US5201745A (en) * | 1988-03-15 | 1993-04-13 | Imedex | Visceral surgery patch |
US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
US5206028A (en) * | 1991-02-11 | 1993-04-27 | Li Shu Tung | Dense collagen membrane matrices for medical uses |
US5246441A (en) * | 1989-09-08 | 1993-09-21 | Linvatec Corporation | Bioabsorbable tack for joining bodily tissue |
US5258043A (en) * | 1987-07-20 | 1993-11-02 | Regen Corporation | Method for making a prosthetic intervertebral disc |
US5259835A (en) * | 1991-08-29 | 1993-11-09 | Tri-Point Medical L.P. | Wound closure means and method using flowable adhesive |
US5306311A (en) * | 1987-07-20 | 1994-04-26 | Regen Corporation | Prosthetic articular cartilage |
US5354283A (en) * | 1994-01-07 | 1994-10-11 | Little Rapids Corporation | Trocar retention apparatus |
US5403338A (en) * | 1992-01-21 | 1995-04-04 | Scanlan International, Inc. | Punch for opening passages between two compartments |
US5423858A (en) * | 1993-09-30 | 1995-06-13 | United States Surgical Corporation | Septoplasty fasteners and device for applying same |
US5470911A (en) * | 1988-11-21 | 1995-11-28 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5544552A (en) * | 1993-01-04 | 1996-08-13 | Axel Kirsch | Tool for setting a fastening nail |
US5567806A (en) * | 1991-08-02 | 1996-10-22 | Abdul-Malak; Nabil | Collagen crosslinked with a crosslinking agent for the manufacture of a suturable, biocompatible slowresorbing membrane, and such a membrane |
US5569252A (en) * | 1994-09-27 | 1996-10-29 | Justin; Daniel F. | Device for repairing a meniscal tear in a knee and method |
US5658343A (en) * | 1994-07-11 | 1997-08-19 | Sulzer Medizinaltechnik Ag | Areal implant |
US5713374A (en) * | 1995-02-10 | 1998-02-03 | The Hospital For Joint Diseases Orthopaedic Institute | Fixation method for the attachment of wound repair materials to cartilage defects |
US5736372A (en) * | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US5769899A (en) * | 1994-08-12 | 1998-06-23 | Matrix Biotechnologies, Inc. | Cartilage repair unit |
US5837278A (en) * | 1994-01-06 | 1998-11-17 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Resorbable collagen membrane for use in guided tissue regeneration |
US5842477A (en) * | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
US5853746A (en) * | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
US5891455A (en) * | 1993-03-03 | 1999-04-06 | Sittinger; Michael | Process for producing an implant from cell cultures |
US5902741A (en) * | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US5932459A (en) * | 1995-10-20 | 1999-08-03 | Sittinger; Michael | Artificial tissues, methods for the production and the use thereof |
US6007539A (en) * | 1996-01-17 | 1999-12-28 | Axel Kirsch | Fastening nail |
US6080194A (en) * | 1995-02-10 | 2000-06-27 | The Hospital For Joint Disease Orthopaedic Institute | Multi-stage collagen-based template or implant for use in the repair of cartilage lesions |
US6132463A (en) * | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
US6187053B1 (en) * | 1996-11-16 | 2001-02-13 | Will Minuth | Process for producing a natural implant |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH632922A5 (en) | 1978-10-06 | 1982-11-15 | Sulzer Ag | Anchorage pin for bone implants |
US4620327A (en) | 1984-07-05 | 1986-11-04 | Caplan Arnold I | Process of adapting soluble bone protein for use in stimulating osteoinduction |
GB8705985D0 (en) | 1987-03-13 | 1987-04-15 | Geistlich Soehne Ag | Dressings |
CA1329089C (en) | 1987-09-02 | 1994-05-03 | Russell Warren | Surgical fastener |
NZ226170A (en) | 1987-09-18 | 1990-07-26 | Ethicon Inc | Stable freeze-dried pharmaceutical composition containing epidermal growth factor |
WO1989004646A1 (en) | 1987-11-13 | 1989-06-01 | Jefferies Steven R | Bone repair material and delayed drug delivery |
JP2820415B2 (en) | 1988-03-14 | 1998-11-05 | ティーエイチエム・バイオメディカル・インコーポレイテッド | Biodegradable and osteogenic graft bone graft substitute composition |
US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
US5108436A (en) | 1988-09-29 | 1992-04-28 | Collagen Corporation | Implant fixation |
IE61346B1 (en) | 1988-11-02 | 1994-11-02 | Genentech Inc | A permeable material to fit around the teeth or gums of a mammal |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
WO1990009783A1 (en) | 1989-02-22 | 1990-09-07 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
WO1990013302A1 (en) | 1989-04-28 | 1990-11-15 | Brigham And Women's Hospital | Novel materials and methods for guided tissue regeneration |
US6413511B1 (en) | 1990-12-20 | 2002-07-02 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide |
SE9101853D0 (en) | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | IMPROVED TISSUE ASHESIVE |
US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
US5326357A (en) | 1992-03-18 | 1994-07-05 | Mount Sinai Hospital Corporation | Reconstituted cartridge tissue |
WO1994000484A1 (en) | 1992-06-22 | 1994-01-06 | Young Henry E | Scar inhibitory factor and use thereof |
WO1994009118A1 (en) | 1992-10-13 | 1994-04-28 | The General Hospital Corporation | Immortalized human chondrocytes |
DE4431598C2 (en) | 1993-03-03 | 1997-03-20 | Michael Sittinger | Process for producing an implant from cell cultures |
CA2130295A1 (en) | 1993-08-26 | 1995-02-27 | Richard A. Berg | Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery |
CA2142209A1 (en) | 1994-03-29 | 1995-09-30 | George H. Chu | Collagen implants having improved tensile properties |
AU2435495A (en) | 1994-05-05 | 1995-11-29 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
DE4425456A1 (en) | 1994-09-07 | 1996-03-21 | Matthias Dr Med Honl | Bone saw for concentric cylindrical or part spherical cuts |
GB9721585D0 (en) | 1997-10-10 | 1997-12-10 | Geistlich Soehne Ag | Chemical product |
GB9503492D0 (en) | 1995-02-22 | 1995-04-12 | Ed Geistlich S Hne A G F R Che | Chemical product |
DE19540487A1 (en) | 1995-10-20 | 1997-04-24 | Olaf Schultz | Cell interaction system for induction of artificial 3-dimensional tissue |
DE19654884C2 (en) | 1996-03-04 | 1999-07-29 | Kirsch Axel | Molded body |
JP3754708B2 (en) | 1996-06-04 | 2006-03-15 | ツィマー ゲーエム ベーハー | Method for producing cartilage tissue and implant for repairing endochondral and osteochondral defects and arrangement for carrying out the method |
US5989269A (en) * | 1996-08-30 | 1999-11-23 | Vts Holdings L.L.C. | Method, instruments and kit for autologous transplantation |
EP0842670A1 (en) | 1996-11-13 | 1998-05-20 | Katsunari Nishihara | Biomedical materials |
DE19648876C2 (en) | 1996-11-16 | 1999-10-07 | Will Minuth | Method of making a natural implant |
JP5105216B2 (en) | 1997-02-13 | 2012-12-26 | ジンマー オーソバイオロジックス,インコーポレーテッド | Implantable putty-like material |
EP1104313A2 (en) * | 1998-08-14 | 2001-06-06 | Verigen Transplantation Service International (VTSI) AG | Methods, instruments and materials for chondrocyte cell transplantation |
EP1204385A1 (en) * | 1999-08-02 | 2002-05-15 | Verigen Transplantation Service International (VTSI) AG | Kit for chondrocyte cell transplantation |
DE19956236A1 (en) | 1999-11-23 | 2001-05-31 | Cognis Deutschland Gmbh | Low-foam wetting agent concentrate for enhancing plant watering comprises an alkyl polyglycoside, a lower alcohol and an anionic cosurfactant |
DE19957388A1 (en) | 1999-11-24 | 2001-06-13 | Michael Sittinger | Chondroinductive and implantable substrates for cartilage healing and protection |
DE10006822A1 (en) | 2000-02-08 | 2001-08-23 | Michael Sittinger | Artificial bone chips, processes for their production and their use |
DE60221576T2 (en) | 2002-01-21 | 2007-12-27 | Fujitsu Ltd., Kawasaki | SOLDERING AND SOLDERING |
-
2001
- 2001-10-03 US US09/970,323 patent/US6569172B2/en not_active Expired - Fee Related
-
2002
- 2002-10-03 CA CA002462306A patent/CA2462306A1/en not_active Abandoned
- 2002-10-03 DE DE60239351T patent/DE60239351D1/en not_active Expired - Lifetime
- 2002-10-03 JP JP2003531890A patent/JP2005504576A/en active Pending
- 2002-10-03 AU AU2002334852A patent/AU2002334852B2/en not_active Expired
- 2002-10-03 WO PCT/US2002/031765 patent/WO2003028545A2/en active IP Right Grant
- 2002-10-03 PL PL368351A patent/PL210783B1/en unknown
- 2002-10-03 RU RU2004113440/15A patent/RU2004113440A/en not_active Application Discontinuation
- 2002-10-03 DK DK02800483.6T patent/DK1437969T3/en active
- 2002-10-03 MX MXPA04003177A patent/MXPA04003177A/en active IP Right Grant
- 2002-10-03 CN CNA028240251A patent/CN1612715A/en active Pending
- 2002-10-03 EP EP02800483A patent/EP1437969B1/en not_active Expired - Lifetime
- 2002-10-03 IL IL16115202A patent/IL161152A0/en unknown
- 2002-10-03 BR BR0213114-5A patent/BR0213114A/en not_active Application Discontinuation
- 2002-10-03 AT AT02800483T patent/ATE499887T1/en not_active IP Right Cessation
-
2003
- 2003-03-26 US US10/397,404 patent/US7137989B2/en not_active Expired - Fee Related
-
2004
- 2004-09-10 HK HK04106893.1A patent/HK1064021A1/en not_active IP Right Cessation
-
2006
- 2006-03-14 US US11/375,183 patent/US20060167483A1/en not_active Abandoned
Patent Citations (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4385404A (en) * | 1980-02-21 | 1983-05-31 | J. & P. Coats, Limited | Device and method for use in the treatment of damaged articular surfaces of human joints |
US4649918A (en) * | 1980-09-03 | 1987-03-17 | Custom Medical Devices, Inc. | Bone core removing tool |
US4553272A (en) * | 1981-02-26 | 1985-11-19 | University Of Pittsburgh | Regeneration of living tissues by growth of isolated cells in porous implant and product thereof |
US4393874A (en) * | 1982-04-26 | 1983-07-19 | Telectronics Pty. Ltd. | Bradycardia event counting and reporting pacer |
US4642120A (en) * | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
US4559936A (en) * | 1983-09-29 | 1985-12-24 | Hill Edward B | Bone plugging apparatus |
US4681588A (en) * | 1983-10-20 | 1987-07-21 | Vettivetpillai Ketharanathan | Biomaterial |
US4789663A (en) * | 1984-07-06 | 1988-12-06 | Collagen Corporation | Methods of bone repair using collagen |
US4877020A (en) * | 1984-11-30 | 1989-10-31 | Vich Jose M O | Apparatus for bone graft |
US4642117A (en) * | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
US5902741A (en) * | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US5736372A (en) * | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
US5041138A (en) * | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
US4846835A (en) * | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
US5258043A (en) * | 1987-07-20 | 1993-11-02 | Regen Corporation | Method for making a prosthetic intervertebral disc |
US5306311A (en) * | 1987-07-20 | 1994-04-26 | Regen Corporation | Prosthetic articular cartilage |
US5158574A (en) * | 1987-07-20 | 1992-10-27 | Regen Corporation | Prosthetic meniscus |
US5201745A (en) * | 1988-03-15 | 1993-04-13 | Imedex | Visceral surgery patch |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
US5470911A (en) * | 1988-11-21 | 1995-11-28 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5092883A (en) * | 1988-12-28 | 1992-03-03 | Eppley Barry L | Method for promoting soft connective tissue growth and repair in mammals |
US5116374A (en) * | 1989-03-02 | 1992-05-26 | Regen Corporation | Prosthetic meniscus |
US5062845A (en) * | 1989-05-10 | 1991-11-05 | Spine-Tech, Inc. | Method of making an intervertebral reamer |
US5246441A (en) * | 1989-09-08 | 1993-09-21 | Linvatec Corporation | Bioabsorbable tack for joining bodily tissue |
US5067964A (en) * | 1989-12-13 | 1991-11-26 | Stryker Corporation | Articular surface repair |
US5019108A (en) * | 1990-02-02 | 1991-05-28 | Bertin Kim C | Modular implant |
US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
US5853746A (en) * | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
US5206028A (en) * | 1991-02-11 | 1993-04-27 | Li Shu Tung | Dense collagen membrane matrices for medical uses |
US5567806A (en) * | 1991-08-02 | 1996-10-22 | Abdul-Malak; Nabil | Collagen crosslinked with a crosslinking agent for the manufacture of a suturable, biocompatible slowresorbing membrane, and such a membrane |
US5445597A (en) * | 1991-08-29 | 1995-08-29 | Tri-Point Medical L.P. | Wound closure means using flowable adhesive |
US5259835A (en) * | 1991-08-29 | 1993-11-09 | Tri-Point Medical L.P. | Wound closure means and method using flowable adhesive |
US5403338A (en) * | 1992-01-21 | 1995-04-04 | Scanlan International, Inc. | Punch for opening passages between two compartments |
US5544552A (en) * | 1993-01-04 | 1996-08-13 | Axel Kirsch | Tool for setting a fastening nail |
US5891455A (en) * | 1993-03-03 | 1999-04-06 | Sittinger; Michael | Process for producing an implant from cell cultures |
US5423858A (en) * | 1993-09-30 | 1995-06-13 | United States Surgical Corporation | Septoplasty fasteners and device for applying same |
US5837278A (en) * | 1994-01-06 | 1998-11-17 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Resorbable collagen membrane for use in guided tissue regeneration |
US5354283A (en) * | 1994-01-07 | 1994-10-11 | Little Rapids Corporation | Trocar retention apparatus |
US5658343A (en) * | 1994-07-11 | 1997-08-19 | Sulzer Medizinaltechnik Ag | Areal implant |
US5769899A (en) * | 1994-08-12 | 1998-06-23 | Matrix Biotechnologies, Inc. | Cartilage repair unit |
US5569252A (en) * | 1994-09-27 | 1996-10-29 | Justin; Daniel F. | Device for repairing a meniscal tear in a knee and method |
US5713374A (en) * | 1995-02-10 | 1998-02-03 | The Hospital For Joint Diseases Orthopaedic Institute | Fixation method for the attachment of wound repair materials to cartilage defects |
US6080194A (en) * | 1995-02-10 | 2000-06-27 | The Hospital For Joint Disease Orthopaedic Institute | Multi-stage collagen-based template or implant for use in the repair of cartilage lesions |
US6132463A (en) * | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
US5932459A (en) * | 1995-10-20 | 1999-08-03 | Sittinger; Michael | Artificial tissues, methods for the production and the use thereof |
US6143501A (en) * | 1995-10-20 | 2000-11-07 | Sittinger; Michael | Artificial tissues, methods for the production and the use thereof |
US6007539A (en) * | 1996-01-17 | 1999-12-28 | Axel Kirsch | Fastening nail |
US5842477A (en) * | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
US6187053B1 (en) * | 1996-11-16 | 2001-02-13 | Will Minuth | Process for producing a natural implant |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130226185A1 (en) * | 2000-01-14 | 2013-08-29 | Bonutti Skeletal Innovations Llc | Femoral guide for knee surgery |
US9192459B2 (en) | 2000-01-14 | 2015-11-24 | Bonutti Skeletal Innovations Llc | Method of performing total knee arthroplasty |
US9101443B2 (en) | 2000-01-14 | 2015-08-11 | Bonutti Skeletal Innovations Llc | Methods for robotic arthroplasty |
US8784495B2 (en) | 2000-01-14 | 2014-07-22 | Bonutti Skeletal Innovations Llc | Segmental knee arthroplasty |
USRE42208E1 (en) | 2003-04-29 | 2011-03-08 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
USRE43258E1 (en) | 2003-04-29 | 2012-03-20 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US8221500B2 (en) | 2003-05-16 | 2012-07-17 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US8292968B2 (en) | 2004-10-12 | 2012-10-23 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
US9701940B2 (en) | 2005-09-19 | 2017-07-11 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
US8906110B2 (en) | 2007-01-24 | 2014-12-09 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
US20090234452A1 (en) * | 2008-03-06 | 2009-09-17 | Steiner Anton J | Instrumentation and method for repair of meniscus tissue |
US8152846B2 (en) * | 2008-03-06 | 2012-04-10 | Musculoskeletal Transplant Foundation | Instrumentation and method for repair of meniscus tissue |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US11555172B2 (en) | 2014-12-02 | 2023-01-17 | Ocugen, Inc. | Cell and tissue culture container |
Also Published As
Publication number | Publication date |
---|---|
RU2004113440A (en) | 2005-03-20 |
WO2003028545A3 (en) | 2003-06-19 |
EP1437969B1 (en) | 2011-03-02 |
BR0213114A (en) | 2004-09-21 |
HK1064021A1 (en) | 2005-01-21 |
IL161152A0 (en) | 2004-08-31 |
US7137989B2 (en) | 2006-11-21 |
EP1437969A4 (en) | 2008-06-11 |
DE60239351D1 (en) | 2011-04-14 |
US20020151986A1 (en) | 2002-10-17 |
WO2003028545A2 (en) | 2003-04-10 |
CA2462306A1 (en) | 2003-04-10 |
DK1437969T3 (en) | 2011-05-02 |
US20040019361A1 (en) | 2004-01-29 |
US6569172B2 (en) | 2003-05-27 |
ATE499887T1 (en) | 2011-03-15 |
EP1437969A2 (en) | 2004-07-21 |
PL210783B1 (en) | 2012-02-29 |
JP2005504576A (en) | 2005-02-17 |
AU2002334852B2 (en) | 2007-08-09 |
PL368351A1 (en) | 2005-03-21 |
CN1612715A (en) | 2005-05-04 |
MXPA04003177A (en) | 2005-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6569172B2 (en) | Method, instruments, and kit for autologous transplantation | |
US6599301B2 (en) | Method, instruments, and kit for autologous transplantation | |
AU2002334852A1 (en) | Method, instruments, and kit for autologous transplantation | |
AU775219B2 (en) | Method, instruments and kit for autologous transplantation | |
AU781216B2 (en) | Method, instruments and kit for autologous transplantation | |
AU2007234527A1 (en) | Method, instruments and kit for autologous transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |